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RESUMO 
INTRODUÇÃO: Os tumores de células germinativas testiculares (TCGT) constituem 
aproximadamente 1% de todos os tumores malignos no sexo masculino. No entanto, 
representam a neoplasia mais comum nos homens em idade jovem, nos países mais 
desenvolvidos. Os TCGT dividem-se em dois grupos: os relacionados com a neoplasia de 
células germinativas in situ (NCGIS) e os não relacionados. A grande maioria dos TCGT é 
representada pelo grupo de tumores relacionados com a NCGIS, os quais incluem dois 
subtipos principais, nomeadamente os seminomas (SE) e os tumores não seminomatosos 
(NS). Os tumores NS incluem ainda quatro subtipos principais: carcinoma embrionário 
(CE), tumor do saco vitelino (SV) do tipo pós-pubertal, coriocarcinoma (CC) e teratoma 
(TE) do tipo pós-pubertal. Todos estes subtipos de tumores NS podem surgir combinados 
entre si e mesmo em combinação com SE, constituindo um grupo referido como tumores 
de células germinativas mistos. Como se torna evidente, os TCGT são um grupo de 
tumores heterogéneo tanto a nível patológico como a nível clínico, apesar da sua grande 
maioria ter origem na mesma via de tumorigénese e partilhar a mesma alteração genética 
básica. Assim, a descoberta de novos biomarcadores baseados na alteração do estado de 
metilação no promotor de genes pode ser promissora na discriminação entre os diferentes 
subtipos de TCGT, incrementando a acuidade do diagnóstico e auxiliando na determinação 
do prognóstico e na monitorização dos doentes. 
OBJETIVOS: O principal objetivo deste estudo foi avaliar o perfil de metilação de um painel 
de cinco genes - CRIPTO, HOXA9, MGMT, RASSF1A e SCGB3A1 – nos principais 
subtipos de TCGT. Especificamente, pretendeu-se avaliar se o padrão de metilação destes 
genes estava associado com os diferentes subtipos de TCGT. Adicionalmente, foi avaliada 
a associação entre a metilação do promotor destes cinco genes e os parâmetros clinico-
patológicos, bem como o potencial valor de prognóstico.  
MATERIAIS E MÉTODOS: Os níveis de metilação dos promotores dos genes CRIPTO, 
HOXA9, MGMT, RASSF1A e SCGB3A1 foram avaliados através de PCR (Polymerase 
chain reaction) específico de metilação, realizado em ADN genómico após modificação por 
bissulfito de sódio. Este ADN foi obtido a partir de amostras de tecido fixadas em formol e 
incluídas em parafina, provenientes de uma coorte de 161 doentes com TCGT e 16 
amostras controlo. O valor de diagnóstico e de discriminação destes cinco genes foi 
determinado através da análise de curvas ROC (Receiver operating characteristics). 
Avaliaram-se, também, possíveis associações entre os níveis de metilação do promotor 
destes cinco genes e os parâmetros clinico-patológicos.  
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RESULTADOS: Os níveis de metilação do CRIPTO, HOXA9, MGMT e SCGB3A1 foram 
significativamente superiores nos TCGT relacionados com a NCGIN do que nas amostras 
controlo. Particularmente, o painel constituído por CRIPTO/HOXA9/SCGB3A1 apresentou 
um elevado desempenho de diagnóstico para tumores NS com todos os parâmetros acima 
de 90%, exceto especificidade e valor preditivo negativo. Os níveis de metilação do 
RASSF1A distinguiram as amostras de SE puros das amostras controlo com todos os 
parâmetros de desempenho de diagnóstico acima de 73%. Todos os cinco genes 
candidatos discriminaram significativamente SE puros de tumores NS, com níveis de 
metilação mais elevados observados nas amostras de tumores NS. Definiu-se, assim, um 
painel de genes constituído por HOXA9 e RASSF1A para discriminação entre SE puros e 
tumores NS, cuja sensibilidade, especificidade, precisão e valor de área sob a curva foram 
de 90,1%, 81,6%, 87,4% e 0,904, respetivamente. Adicionalmente, observaram-se 
diferenças significativas nos níveis de metilação do CRIPTO, MGMT e RASSF1A quando 
comparados os SE puros com os SE como componentes dos tumores de células 
germinativas mistos, apenas do MGMT entre os CEs puros e as correspondentes formas 
mistas e do HOXA9, RASSF1A e SCGB3A1 entre os TEs pós-pubertais puros e os TEs 
pós-pubertais provenientes de tumores mistos. Observou-se, também, que os níveis de 
metilação do HOXA9, RASSF1A e SCGB3A1 foram significativamente superiores nos CEs 
puros quando comparados com os SE puros e, simultaneamente, que a metilação do 
promotor do CRIPTO foi significativamente superior nos TEs pós-pubertais puros quando 
comparados com os SE puros e com os CEs puros, individualmente. Não obstante, os 
níveis de metilação do HOXA9 e do RASSF1A foram significativamente mais baixos nos 
SE mistos quando individualmente comparados com os restantes subtipos de TCGT em 
contexto de tumores mistos. Os níveis de metilação do RASSF1A foram significativamente 
superiores nos tumores do SV pós-pubertais e nos CCs ambos em contexto de TCGT 
mistos quando comparados com os CEs mistos. Os níveis de metilação do SCGB3A1 
foram significativamente superiores nos tumores do SV pós-pubertais, CCs e TEs pós-
pubertais em contexto de TCGT mistos quando individualmente comparados com os SE 
mistos ou com os CEs mistos. Os níveis de metilação do MGMT foram apenas 
significativamente diferentes entre os SE mistos e os TEs mistos do tipo pós-pubertal, com 
os níveis mais elevados observados neste último componente.  
Os níveis de metilação do CRIPTO e HOXA9 foram também significativamente diferentes 
entre os tumores do SV pré-pubertais e os tumores do SV pós-pubertais como 
componentes dos TCGT mistos. Observaram-se, igualmente, diferenças significativas nos 
níveis de metilação do HOXA9, MGMT e SCGB3A1 entre os TEs pré-pubertais e os TEs 
pós-pubertais em contexto de tumores mistos.  
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A sensibilidade dos níveis de metilação do CRIPTO na deteção de TCGT relacionados com 
a NCGIS foi superior à descrita para cada um dos marcadores tumorais séricos medidos 
antes da orquidectomia (sensibilidade: 65,8% vs. 35% de alfa-fetoproteína, 51,8% de beta-
gonadotropina coriónica humana e 42,9% de desidrogenase láctica). Adicionalmente, 
observaram-se níveis mais elevados de metilação do HOXA9, RASSF1A e SCGB3A1 em 
doentes em estadio mais avançado, particularmente em doentes em estadio III quando 
comparados com doentes em estadio I ou estadio II. Os níveis de metilação destes três 
genes associaram-se também com o estadio baseado na estratificação em grupos de 
prognóstico dos doentes com doença metastática, com os níveis mais elevados 
observados nos doentes dos grupos de mau ou prognóstico intermédio, comparado com 
os doentes do grupo de bom prognóstico. 
CONCLUSÕES E PERSPETIVAS FUTURAS: Este estudo mostrou que a utilização de 
biomarcadores baseados na metilação para a deteção de TCGT é promissora, com 
sensibilidade superior à dos marcadores tumorais séricos clássicos. Foram, também, 
observadas importantes diferenças moleculares a nível epigenético entre todos os subtipos 
de TCGT, contribuindo para uma melhor compreensão destes tumores tão heterogéneos. 
Adicionalmente, os níveis de metilação destes cinco genes poderão ser úteis para melhorar 
as ferramentas de estratificação de risco clínico, em termos de estadio e prognóstico. 
Contudo, são necessários estudos adicionais, englobando maiores coortes de doentes, 
bem como dadores saudáveis, para confirmação da utilidade destes biomarcadores na 
prática clínica. A validação destes resultados em biópsias líquidas é também necessária 
para determinar o potencial de um novo método minimamente invasivo na deteção e 
discriminação dos subtipos de TCGT, com impacto na monitorização dos doentes. 
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ABSTRACT 
BACKGROUND: Testicular germ cell tumors (TGCT) account for approximately 1% of all 
male malignant tumors, but represent the most common neoplasm in young Caucasian men 
in developed countries. TGCT can be divided into TGCT related to germ cell neoplasia in 
situ (GCNIS) and unrelated ones. The former represents the vast majority of TGCT and 
include seminoma (SE) and nonseminomatous tumors (NST), being the last further divided 
into embryonal carcinoma (EmbrCa), postpubertal-type yolk-sac tumor (YST), 
choriocarcinoma (CH) and postpubertal-type teratoma (TE). Different combinations of NST 
components and even SE may occur in a class of tumors referred to as mixed germ cell 
tumors. TGCT are a heterogeneous group of tumors at pathological and clinical levels, 
although most originate from the same tumorigenic pathway and are characterized by a 
common genetic abnormality. Thus, the discovery of new methylation-based biomarkers 
may show promise for discrimination between TGCT subtypes, providing additional relevant 
information at diagnosis to support therapeutic decisions and patient monitoring.  
AIMS: The main objective of this study was to evaluate a promoter methylation profile based 
on a five-gene panel constituted by CRIPTO, HOXA9, MGMT, RASSF1A and SCGB3A1 
genes, in TGCT subtypes. Specifically, we aimed to assess whether methylation patterns 
might be associated with different TGCT subtypes. Moreover, we also evaluated the 
association between genes’ promoter methylation and standard clinicopathological 
parameters, and determined their potential prognostic value.  
MATERIALS AND METHODS: CRIPTO, HOXA9, MGMT, RASSF1A and SCGB3A1 
promoter methylation levels were evaluated in a cohort of 161 TGCT patients and 16 
controls by quantitative methylation-specific polymerase chain reaction (qMSP), using 
bisulfite-modified genomic DNA, obtained from formalin-fixed paraffin-embedded tissue 
samples. Receiver operating characteristics (ROC) curve was performed to evaluate the 
diagnostic and discriminatory power of the panel. Correlation between standard 
clinicopathological parameters and genes’ promoter methylation levels was also assessed.  
RESULTS: CRIPTO, HOXA9, MGMT and SCGB3A1 methylation levels were significantly 
higher in GCNIS-related TGCT compared to controls. Specifically, 
CRIPTO/HOXA9/SCGB3A1 panel displayed high diagnostic coverage of NST with all 
performance parameters above of 90%, with exception of specificity and negative predictive 
value (NPV). RASSF1A methylation levels may distinguish pure SE from controls with all 
diagnostic parameters above 73%. All five candidate genes were able to significantly 
discriminate between pure SE and NST with the higher methylation levels depicted in NST. 
HOXA9/RASSF1A panel showed high discriminatory performance for pure SE vs. NST, 
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with 90.1% sensitivity, 81.6% specificity, 87.4% accuracy and area under the curve (AUC) 
of 0.904. Moreover, significant differences for CRIPTO, MGMT and RASSF1A methylation 
levels were depicted comparing pure SE with SE as component of mixed TGCT, for MGMT 
between pure EmbrCa and matching mixed EmbrCa and for HOXA9, RASSF1A and 
SCGB3A1 between pure postpubertal-type TE and mixed postpubertal-type TE. HOXA9, 
RASSF1A and SCGB3A1 methylation levels were also significantly higher in pure EmbrCa 
compared with pure SE, whereas CRIPTO promoter methylation levels were significantly 
higher in pure postpubertal-type TE compared to pure SE and pure EmbrCa. Moreover, 
HOXA9 and RASSF1A methylation levels were significantly lower in mixed SE when 
individually compared with the remaining mixed TGCT subtypes. Furthermore, RASSF1A 
methylation levels were also significantly higher in mixed postpubertal-type YST and mixed 
CH when compared with mixed EmbrCa. SCGB3A1 methylation levels were significantly 
higher in mixed postpubertal-type YST, mixed CH and mixed postpubertal-type TE when 
individually compared with mixed SE or mixed EmbrCa. MGMT methylation levels were only 
significantly different between mixed SE and mixed postpubertal-type TE with the highest 
levels depicted in the last component. A significant difference was also observed for 
CRIPTO and HOXA9 methylation levels between prepubertal-type YST and postpubertal-
type YST as component of mixed germ cell tumors and for HOXA9, MGMT and SCGB3A1 
methylation levels between prepubertal-type TE and mixed postpubertal-type TE.  
Diagnostic information on GCNIS-related TGCT was improved when considering CRIPTO 
methylation levels than the three classical serum tumor markers measured before 
orchiectomy (sensitivity: 65.8% vs. 35.0% of alpha-fetoprotein, 51.8% of beta-human 
chorionic gonadotropin and 42.9% of lactate dehydrogenase). Additionally, patients with 
advanced group staging disclosed the highest methylation levels of HOXA9, RASSF1A and 
SCGB3A1, with the highest methylation levels depicted in patients with stage III disease 
compared with patients at stage I or stage II. Promoter methylation levels of these genes 
panel were also significantly associated with prognostic-based staging of TGCT with the 
higher methylation levels depicted by patients classified as intermediate and poor prognosis 
compared with good prognosis patients. 
CONCLUSIONS AND FUTURE PERSPECTIVES: This study illustrated the promising use 
of methylation-based biomarkers for TGCT detection, with higher sensitivity than the 
standard classical serological markers. We also observed molecular differences at 
epigenetic level between all TGCT subtypes, which might aid in management of these 
heterogeneous tumors. Moreover, we also showed the potential value of combinations of 
these five genes promoter methylation levels for improving risk stratification and 
prognostication of TGCT patients. However, further studies using larger cohorts of patients 
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and healthy donors are mandatory to confirm the usefulness of these promising biomarkers 
in clinical practice. Validation of these results in liquid biopsies might also provide a novel 
minimally invasive tool for detection and discrimination among TGCT subtypes, as well as 
patient monitoring.  
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I. INTRODUCTION 
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1. TESTICULAR GERM CELL TUMORS  
Testicular germ cell tumors (TGCT) are a very complex and heterogeneous group of 
neoplasms characterized by diagnostic, therapeutic and prognostic particularities. 
Currently, according to the 2016 World Health Organization (WHO) classification, TGCT 
are divided into two main categories: those related to germ cell neoplasia in situ (GCNIS) 
and the unrelated ones [1]. Importantly, since TGCT unrelated to GCNIS are extremely rare, 
the global epidemiological data as well as the risk factors reported in the literature for TGCT 
only refers to TGCT related to GCNIS. 
 
1.1. Epidemiology 
TGCT are relatively rare, accounting for about 1% of all male cancers worldwide. 
Nevertheless, these tumors constitute the most common cancer in young Caucasian men 
between 15 and 44 years in developed countries [2-4]. Indeed, the highest incidence rates 
occur in more developed and industrialized countries, particularly in Northern and Western 
Europe, while the lowest rates correspond to Asia and Africa (Figure 1) [2, 4].  
Figure 1. (A) Worldwide incidence of testicular germ cell tumors; (B) Worldwide mortality of testicular germ cell 
tumors. (From Globocan 2012 [3]). 
 
1.2. Risk Factors 
Currently, there are several risk factors established for TGCT development, specifically 
those related with genetic and environmental factors [5, 6]. About 25% of TGCT cases are 
attributable to genetic susceptibility which might be explained, in part, by the presence of 
gr/gr microdeletion (removal of part of AZFc region) at Y chromosome [7]. This molecular 
alteration consists in a low penetrance susceptibility allele, whose presence, possibly due 
to its relation with male infertility, augments in 2 to 3-fold the risk of sporadic and familial 
TGCT development, respectively [8-10]. Moreover, PDE11A gene mutations have also 
been described as risk modifier for familial TGCT, such as reported by Horvath et al., in 
(A) (B) 
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which 19% of families studied displayed all PDE11A-gene variants [10, 11]. Additionally, 
United Kingdom (UK) genome-wide association study for TGCT susceptibility reported other 
susceptibility loci (KITLG, SPRY4 and BAK1) associated with 6-fold risk of TGCT 
development for KITLG and 2-fold for variants in the region of SPRY4 and BAK1 [12]. 
Familial predisposition is a well-established risk factor for TGCT development representing 
one of the strongest known risk factors for TGCT, as proven by Hemminki et al., in which 
the overall familial risks were 3.78 and 8.78 for son-father and brothers relations, 
respectively [6, 8, 13, 14]. Although, other risk factors have been described, namely patients 
with cryptorchidism history (2 to 8-fold increased risk of TGCT development) [15, 16], 
subfertility/infertility (increased risk for TGCT in 1.6-2.8 times) [17-20] and testicular 
microlithíasis (13.2 relative risk) [21]. Furthermore, it was also described that patients with 
TGCT in one testis have a 25-fold increased risk to develop a contralateral tumor [15]. 
Somatic genetic alterations such as activating mutations in KIT and KRAS oncogenes 
and pathognomonic gain of chromosome 12p as isochromosome 12p (i12p) have been 
reported in TGCT and, therefore, may be associated with the risk of developing these 
neoplasms [10]. KIT mutation/amplification is present in about 20% of seminomas (SE) and 
rarely seen in nonseminomatous tumors (NST), whereas KRAS mutations are described in 
about 10% of TGCT [22-24]. 
On the other hand, perinatal factors such as maternal bleeding, birth order, number of 
siblings, inguinal hernia, twinning, low birth weight and environmental risk factors namely 
dyethylstillbestrol exposure in utero, organochloride pesticides exposure, firefighting, 
aircraft maintenance, leather and metal workers have also been associated with TGCT 
development [5, 6, 15, 25]. Maternal smoking, diet, physical exercise and marijuana intake 
have also been associated with increased risk of TGCT development [5, 6, 25]. It has also 
been reported a possible association between genvironmental factors and an increased risk 
of TGCT. These consist in the combination of genetic and environmental factors, resulting 
in the called testicular dysgenesis syndrome, which comprises, among others, 
cryptorchidism and testicular atrophy [5, 26, 27]. 
 
1.3. Testicular Germ Cell Tumors Subtypes 
TGCT can be generally referred as GCNIS-derived and non-GCNIS-derived tumors [1]. 
The main subtypes of each category are grouped in Table 1 and illustrated in Figure 2.  
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Table 1. Classification of testicular germ cell tumors, according to WHO 2016. (Adapted from [25]). 
 
 
1.3.1. Testicular Germ Cell Tumors Related to Germ Cell Neoplasia in 
situ  
TGCT related to GCNIS represent the vast majority of TGCT and can be divided into 
SE and NST, with the last further including different subtypes according to its differentiation 
(Table 1) [25]. These tumors share many characteristics: all of them result from GCNIS cells 
progression, arise from postpubertal testis, are cytogenetically similar (all showing the gain 
of chromosome 12p, mainly as i12p) and display malignant behavior [1, 25, 28]. 
 
1.3.1.1. Germ Cell Neoplasia in situ  
GCNIS consists of abnormal germ cells/gonocytes whose maturation to 
prespermatogonia was stopped during the normal fetal development [25, 28]. These cells 
remain dormant until puberty and, at this stage, GCNIS cells can progress to SE, which 
represents the default pathway, or to embryonal carcinoma cells whose diverse 
differentiation pathways originate the NST subtypes: stem-cell like embryonal carcinoma 
(EmbrCa), postpubertal-type yolk-sac tumor (YST) and choriocarcinoma (CH), both 
representing the extraembryonic lineages; and postpubertal-type teratoma (TE), 
representing the somatic lineage [25, 28] (Figure 2). Since GCNIS is found in almost all SE 
and NST, it is considered the noninvasive precursor for TGCT. About 50% of patients 
diagnosed with GCNIS will progress to an invasive TGCT within 5 years, whereas 70% will 
5 
 
progress to an invasive TGCT in 7 years, thus, suggesting that almost all GCNIS progress 
to overt cancer [27, 29]. Furthermore, GCNIS is found in about 5% of contralateral testis of 
previous TGCT patients [30]. 
GCNIS cells express various pluripotency markers such as POU5F1 (OCT3/4), 
placental alkaline phosphatase (PLAP), AP-2Ȗ, NANOG, LIN28 and podoplanin, which 
might assist in diagnosis [31-35].  
The highest risk to develop GCNIS has been associated with sex development disorders 
(70% of prevalence) and testicular dysgenesis syndrome [35, 36], being testicular biopsy 
the gold standard for its detection [29, 30]. 
Epigenetically, GCNIS cells are characterized by global DNA hypomethylation [37], 
presence of permissive histone modifications [38] and overexpression of miR-371-373 [39].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Pathogenesis of testicular germ cell tumors (TGCT). TGCT can be divided in two major categories: 
those related to germ cell neoplasia in situ (GCNIS) and the unrelated ones. GCNIS originates from a dormant, 
transformed primordial germ cell (PGC) or gonocyte, whose maturation to prespermatogonia was prevented 
possible due to an early polyploidization. After puberty, these transformed germ cells progress originating 
seminoma or one of the nonseminomatous tumors: stem-cell like embryonal carcinoma, postpubertal-type yolk-
sac tumor and choriocarcinoma (extraembryonic lineages), postpubertal-type teratoma (somatic lineage) and 
mixed germ cell tumors composed by at least two of these different components and possible also seminoma. 
TGCT unrelated to GCNIS include prepubertal-type teratoma and yolk-sac tumor and spermatocytic tumor. 
Prepubertal-type teratoma derives from an embryonic stem cell (ESC), PGC or gonocyte limited in their 
development. Prepubertal-type yolk-sac tumor can result from teratoma cells progression. Spermatocytic tumor 
originates from spermatogonia or spermatocyte. Gain of chromosome 9 as well as activating mutations in HRAS 
and FGFR3 genes have been associated to spermatocytic tumor carcinogenesis. 
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1.3.1.2. Seminoma 
According to the most updated WHO classification, SE is defined as a “malignant germ 
cell tumor whose cells are considered the neoplastic counterparts of the primordial germ 
cells/gonocytes present during early embryonic development” [25].  
SE constitute the most common TGCT subtype, whose pure form represents about 50% 
of cases, with a mean patients’ age at diagnosis of 35 years [25, 27, 28]. SE might also be 
presented as a component of mixed germ cell tumors together with one or more NST 
subtypes [40]. It occurs almost exclusively in postpubertal testis, being extremely rare in 
prepubertal children and in the elderly men (>70 years) [40, 41]. Morphologically, SE are 
similar to GCNIS, and also express PLAP, KIT, OCT3/4, SALL4, SOX17 and podoplanin. 
Conversely, SE cells are negative for CD30, glypican 3, SOX2, alpha-fetoprotein (AFP) and 
beta-human chorionic gonadotropin (ȕ-hCG) [25, 40, 42]. Globally, the standard serum 
tumor markers [AFP, ȕ-hCG and lactate dehydrogenase (LDH)] are not significantly 
elevated in SE tumors, especially in early stages of the disease [25]. 
SE development has been associated with cryptorchidism history and 
immunodeficiency disorders [25]. 
SE are usually sensitive to cisplatin-based chemotherapy and radiotherapy, and display 
an overall good prognosis, although stage-dependent [27]. 
Similarly to GCNIS, the epigenetic pattern of SE cells is characterized by DNA 
hypomethylation and permissive histone modifications [25]. 
 
1.3.1.3. Nonseminomatous Tumor: Embryonal Carcinoma 
EmbrCa is a “malignant germ cell tumor composed of tumor cells resembling embryonic 
stem cells” [25]. EmbrCa represents the second most common TGCT subtype and the most 
common NST subtype, occurring mostly as a component of mixed germ cell tumors (about 
84%) and being rare in its pure form (about 16%) [40, 43]. The mean patients’ age at 
diagnosis ranges between 25 to 35 years and it does not occur in prepubertal patients, 
being rare in men over 50 years [40]. 
Immunohistochemically, EmbrCa cells express OCT3/4, CD30, SOX2, SALL4, 
cytokeratin AE1/AE3, whereas no expression is shown for SOX17, glypican 3, KIT, 
podoplanin, ȕ-hCG, carcinoembryonic antigen and epithelial membrane antigen. The 
expression pattern can be useful to distinguish this NST subtype from other TGCT subtypes 
(SE, YST or CH) [25, 40, 42, 43]. Similarly to SE, elevated serum tumor markers (AFP, ȕ-
hCG and LDH) are not usually found in pure EmbrCa form, unless EmbrCa cells co-exist 
with other TGCT elements [25].  
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Pure EmbrCa is more aggressive than EmbrCa in mixed germ cell tumors, whose 
prognosis depends on disease’s clinical and pathological stage and the proportion of 
EmbrCa cells in mixed tumors [44, 45].  
 
1.3.1.4. Nonseminomatous Tumor: Postpubertal-Type Yolk-Sac 
Tumor 
Postpubertal-type YST is defined as “a malignant germ cell tumor that differentiates to 
resemble extraembryonic structures, including yolk-sac, allantois and extraembryonic 
mesenchyme” [25]. Postpubertal-type YST is extremely rare in its pure form and appears 
predominantly as a component of mixed germ cell tumors (42% of cases) [46, 47]. Patients 
diagnosed with these tumors usually have ages between 15-40 years, with rare cases 
diagnosed in the elderly [25, 48].  
YST cells exhibit immunoreactivity for PLAP, α1-antitrypsine, KIT, SALL4, 
pancytokeratin, AFP and glypican 3, but are negative for ȕ-hCG, OCT3/4 and CD30 [25, 
40, 49, 50]. There is a strong correlation between elevated AFP serum levels and the 
presence of YST, since these levels are seen in more than 95% of YST patients, thus being  
an important diagnostic tool [40, 42]. 
 
1.3.1.5. Nonseminomatous Tumor: Choriocarcinoma 
CH is “a malignant germ cell tumor that differentiates to resemble the trophoblastic cells 
of the extraembryonic chorion, including cytotrophoblastic, intermediate trophoblastic and 
syncytiotrophoblastic cells” [25]. CH is the rarest TGCT, whose pure tumor represent less 
than 1% of TGCT [46, 51, 52]. Patients diagnosed with CH usually have between 20 to 39 
years and often present metastatic disease, contrarily to the others TGCT subtypes. [52]. 
Therefore, CH is the most aggressive form of TGCT, due to the diagnosis at advanced 
stages, early dissemination and hemorrhagic complications [51-53]. Moreover, about 79% 
of patients treated with orchiectomy and chemotherapy decease of the disease within 3 
years [51].  
An important tool for CH diagnosis are the extremely high ȕ-hCG serum levels, which 
often present levels over 50.000 IU/L [51]. Concomitantly, specific symptoms such as 
gynecomastia and hyperthyroidism due ȕ-hCG similarity with luteinizing and thyroid-
stimulating hormones are also common [40]. CH cells express ȕ-hCG, SALL4, GATA3, 
glypican 3, α-inhibin and human placental lactogen [42].  
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1.3.1.6. Nonseminomatous Tumor: Postpubertal-Type Teratoma 
Postpubertal-type TE is “a malignant germ cell tumor composed of several types of 
tissue representing one or more of the germinal layers (endoderm, mesoderm and 
ectoderm). It may be composed exclusively of well-differentiated, mature tissue or have 
immature, embryonic-type tissues” [25]. Forty seven to fifty% of postpubertal-type TE are 
diagnosed as a component of mixed germ cell tumors, whereas pure tumor is quite rare, 
occurring in only 2.7 to 7% of TGCT cases [47, 54]. This tumor mostly affects young adults 
and one-third are metastatic at the time of diagnosis [54]. Although, pure TE is the most 
common component present in patients with recurrent or metastatic disease after treatment, 
it associates with a more favorable prognosis compared to the presence of the other 
metastatic TGCT subtypes [55].  
 
1.3.1.7. Nonseminomatous Tumor: Mixed Germ Cell Tumors 
Mixed germ cell tumors are malignant tumors composed by a mixture of two or more 
malignant TGCT components: at diagnosis, the average patients’ age is of 30 years, being 
extremely rare in prepubertal patients [25, 40]. Mixed tumors that include SE component 
occur later than mixed tumors only composed by NST subtypes [40, 47]. EmbrCa is the 
most frequent subtype of mixed germ cell tumors, followed by postpubertal-type TE, 
postpubertal-type YST, SE and CH. All combinations are possible and usually with more 
than two components. The most common combinations include EmbrCa with postpubertal-
type TE, SE or postpubertal-type YST [42].  
Elevated serum tumor markers correlate with TGCT components present in mixed 
tumors. Specifically, elevated AFP levels indicates the presence of YST elements, whereas 
ȕ-hCG levels are indicative of trophoblastic cells such as CH cells [40, 47]. The different 
constituents (SE and NST) in mixed germ cell tumors are histologically similar to their pure 
forms and their proportions have clinical implications, particularly in stage I tumors, thus 
requiring the assessment of the percentages of each component [40, 56].  
 
1.3.2. Testicular Germ Cell Tumors Unrelated to Germ Cell Neoplasia 
in situ  
TGCT unrelated to GCNIS are very rare and include spermatocytic tumor (ST) and both 
prepubertal-type YST and TE. Contrarily to TGCT related to GCNIS, these are a 
heterogeneous group with a benign behavior characterized by the absence of i12p 
amplification. Prepubertal-type tumors occur in children, although it may be identified in 
postpubertal patients. Postpubertal-type tumors may also occur in prepubertal testis [1].   
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1.3.2.1. Spermatocytic Tumor  
ST is “a germ cell tumor derived from postpubertal-type germ cells, whose tumor cells 
resemble spermatogenic cells, most commonly spermatogonia or early primary 
spermatocytes” [25]. ST accounts only for about 1% of TGCT occurring in a wide range of 
ages (19 to 92 years), but with a global mean of 50 years [57]. These tumors are exclusively 
confined to testis and rarely metastasize, being associated with an excellent prognosis 
except when it progresses to sarcoma, in which a higher metastatic rate is observed [57-
59]. Amplification of chromosome 9 results in DMRT1 gene expression and HRAS and 
FGFR3 mutations have been suggested to trigger tumor development [60, 61]. ST cells do 
not express embryonic germ cell markers like OCT3/4, PLAP, AFP, ȕ-hCG, CD30, whereas  
proteins expressed in spermatogonia such as SALL4, KIT or MAGEA4 are often expressed 
[42, 62]. Epigenetic characterization of these tumors is extremely difficult since the same 
tumor can exhibit several levels of DNA methylation and contain permissive or repressive 
histone modifications [63].  
 
1.3.2.2. Prepubertal-Type Teratoma 
Prepubertal-type TE has a similar definition of postpubertal-type TE, since it is also 
“composed by elements resembling somatic tissues derived from one or more of the 
germinal layers” [25]. However, unlike postpubertal-type TE, prepubertal-type TE is a 
benign tumor thought to be derived from a germ cell that has not undergone malignant 
transformation. Moreover, these tumors particularly occur as a pure tumor and have not 
been associated with metastases or disease recurrence, allowing conservative treatment 
[42, 59, 64]. Prepubertal-type TE occurs at a median age of 13 months [64].  
 
1.3.2.3. Prepubertal-Type Yolk-Sac Tumor 
Prepubertal-type YST has the same definition of postpubertal-type YST, according to 
the 2016 WHO classification [25]. This is a rare tumor, although represents the most 
common TGCT (48% to 62% of cases) in children of 16-20 months [65, 66]. Contrarily to its 
postpubertal counterpart, prepubertal-type YST mostly occurs as a pure tumor with 
extremely rare cases reported as mixed tumors [59, 65]. Prepubertal-type YST exhibits the 
same morphological and immunoexpression patterns of postpubertal-type YST, being AFP 
serum levels elevated in about 95% of the cases [65, 67]. Nonetheless, the elevated values 
should be carefully interpreted, particularly in patients younger than 6 months, since they 
might result from the physiologically elevated values in this particular young patients [65]. 
About 80% of children diagnosed display stage I prepubertal-type YST with good prognosis 
[65].  
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1.4.  Diagnosis and Staging  
The primary diagnostic approach when there is a suspicion of testicular tumor consists 
in a scrotal ultrasonography of both testis, whose sensitivity in detecting testicular cancer is 
almost 100% [68]. The following approaches include chest and abdominopelvic computed 
tomography (CT), as well as measurement of classical serum tumor markers (AFP, ȕ-hCG 
and LDH) for correct diagnosis and disease staging assessment [69]. Nevertheless, due to 
their low sensitivity and specificity, serum tumor markers should be careful interpreted. 
Indeed, only 60% of TGCT patients exhibit elevated serum markers at diagnosis [70]. AFP 
levels might also be elevated in other cancer patients, such as hepatocellular and 
gastrointestinal cancers, as well as in benign liver pathologies. Similarly, elevated ȕ-hCG 
levels might also be associated with neuroendocrine, renal, bladder and lung cancers. 
Some benign and malignant diseases also result in high LDH serum levels [71, 72].  
TGCT clinical staging is ascertained by clinical examination, disease extension 
evaluation (involvement and size of regional lymph nodes, nonregional lymph nodes and 
pulmonary and nonpulmonary metastases) through thorax and abdominopelvic CT and by 
determination of the classical serum tumor markers values before orchiectomy. Thus, extent 
of primary tumor (T), regional lymph nodes involvement (N), distant metastasis (M) and 
status of serum tumor markers (S) can be established [73]. 
Pathologic staging is determined after radical orchiectomy through histopathologic 
evaluation [73]. TGCT preferentially metastasizes through lymphatic channels to 
retroperitoneum rather than to haematogenous spread. In the absence of metastatic 
disease, serum tumor markers should be similar to basal concentrations, after orchiectomy 
[44, 72]. The clinical and pathologic Tumor Node Metastasis (TNM) classification of TGCT 
as well as the different group stages of the disease are described in Table 2 and Table 3, 
respectively.  
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Table 2. Clinical and pathological TNM classification of testicular germ cell tumors. (Adapted from [25, 69, 73]). 
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Table 3. Staging grouping of testicular germ cell tumors. (Adapted from [25, 69, 73]). 
 
1.5. Prognosis and Therapeutic Approaches 
TGCT are one of the most curable solid tumors [44, 72]. About 75% of TGCT patients 
present clinical stage I (80% of SE and 60% of NST) at the time of diagnosis [74]. In this 
stage, about 80% of SE cases and 70% of NST benefit from surgery. Moreover, stage II or 
III patients also present high survival rates after orchiectomy and adjuvant treatment. 
Indeed, the 5-year overall survival rates for localized, regional and distant disease are of 
99.2%, 96% and 73.1%, respectively [75]. Furthermore, late disease relapse only occurs in 
1.4% of SE and 3.2% of NST [76]. In 1997, the International Germ Cancer Collaborative 
Group developed a prognostic-based staging for advanced disease based on histology, 
location of primary tumor, metastases and serum tumor markers values immediately before 
chemotherapy administration, to assist in the decision of further treatment (Table 4) [69, 72, 
77, 78]. 
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Table 4. Prognostic-based staging system for metastatic germ cell cancer (International Germ Cell Cancer 
Collaborative Group). (Adapted from [69, 77, 78]). 
 
Stage I SE patients’ have a higher relapse probability if the tumor is larger than 4 cm 
and invades rete testis [79, 80]. Concerning NST stage I, blood or lymphatic invasion 
constitutes the most important metastases predictor [81]. 
Gold standard treatment of primary TGCT is orchiectomy, then the patients can stay in 
active surveillance (for example in the case of stage I SE) or can be proposed to adjuvant 
treatments, including chemotherapy, radiotherapy or retroperitoneal lymph node dissection, 
according to different stages of the disease (Table 5) [69].  
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Table 5. Summary of the different therapeutic schemes for treatment of testicular germ cell tumors [69]. 
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2. EPIGENETICS  
The term “Epigenetics” was first described by C.H Waddington in 1942 as “causal 
interactions between genes and their products, which bring the phenotype into being”. 
Currently, Epigenetics is defined as the study of phenomena in which heritable and 
reversible changes in gene expression/function occur without altering the DNA sequences 
[82, 83]. 
 
2.1.  Epigenetic Mechanisms 
Epigenetic mechanisms include four major groups of modifications: DNA methylation, 
histone post-translational modifications, histone variants and non-coding RNAs (ncRNAs) 
(Figure 3) [84]. These mechanisms constitute the epigenome machinery and modulate the 
chromatin framework (euchromatin – activated transcription or heterochromatin – silenced 
transcription) which, in turn, culminate in gene expression or repression [84, 85]. Epigenetic 
mechanisms are essential for normal development as well as for maintenance of specific 
gene expression profiles in mammals [86]. Nevertheless, dysregulation of these 
mechanisms are commonly seen in several diseases including cancer, contributing to its 
development and progression through inactivation of tumor suppressor genes (TSG) or 
activation of oncogenes [87]. Because of their reversible characteristics, there has been 
greater interest in studying the epigenetic mechanisms underlying tumorigenesis as well as 
the search for new therapeutic approaches for cancer treatment [86]. 
Figure 3. Representation of four different epigenetic mechanisms. M – 5-methylcytosine; the symbols hexagon 
and triangle represent different translational modifications in N-terminal tails of histones proteins. (CBEG, IPO 
Porto). 
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2.1.1. Non-Coding RNAs 
Most of the genome is composed by non-protein-coding genes, whose transcription 
gives rise to ncRNAs consisting in RNA sequences that do not translate into proteins. In 
fact, only 1.5% of the genome codes into proteins [88, 89]. These ncRNAs are involved in 
gene expression regulation, messenger RNA (mRNA) degradation, splicing, transport and 
translation, having an important role in normal development and disease progression [90]. 
These ncRNAs are generally divided, according to their size, into small non-coding RNAs 
(sncRNAs) (<200 bp), mid-size non-coding RNAs and long non-coding RNAs (lncRNAs) 
(>200 bp). sncRNAs include microRNAs (miRNAs) and PIWI-interacting RNAs, mid-size 
non-coding RNAs include small nucleolar RNAs and lncRNAs comprise large intergenic 
ncRNAs and transcribed ultraconserved regions [88]. The most well studied ncRNAs are 
miRNAs [88]. About 60% of human genes are regulated by miRNAs, which bind to 
complementary sequences at 3’-untranslated region (UTR) of target mRNAs and negatively 
regulate the mRNA translation into proteins through mRNA degradation or inhibition of 
translation initiation [88, 91, 92]. A single miRNA may regulate dozens of target mRNAs at 
the same time and each transcript might be regulated by various miRNAs. This post-
transcriptional regulation mediates multiple processes including cell cycle, metabolism, 
proliferation, differentiation, apoptosis and development. Importantly, miRNAs expression 
dysregulation has been implicated in various cancers [91, 92]. Thus, miRNAs can act as 
oncogenes when are overexpressed, or as TSG when downregulated, having also been 
described as markers for diagnosis, prognosis and as modulators of cancer cells sensitivity 
to chemotherapeutic agents [93-95].  
 
2.1.2. Histone Post-Translation Modifications and Variants 
Chromatin is a DNA packaged state into cells. The basic unit of chromatin is the 
nucleosome composed by an octamer of four proteins (one pair of each H2A, H2B, H3 and 
H4), which is wrapped by 147 base pairs of DNA [96]. Histones represent not only the DNA-
packaging proteins, but are also recognized as important regulators of chromatin dynamic 
[97]. Histones undergo a series of post-translational modifications such as acetylation, 
methylation and phosphorylation, influencing the chromatin conformation [98]. The set of 
different changes that may occur in histone is called “histone code”, which is important in 
various processes such as gene expression and DNA replication and repair [97, 98]. 
Furthermore, excepting H4, the other histones that constitute the nucleosome (H2A, H2B 
and H3) have several histone variants, contributing to more diversification of chromatin 
conformation, important for cellular regulation during development. These variants, 
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contrarily to their canonical counterparts are expressed independently of DNA replication 
[99, 100].  
 
2.1.3. DNA Methylation 
DNA methylation is the most widely studied epigenetic mechanism [86, 87], occurring 
almost exclusively in cytosine residues that precedes guanines in structures named CpG 
dinucleotides (Cytosine-phosphate-Guanine) in mammals [101, 102]. This process is 
catalyzed by a set of enzymes called DNA methyltransferases (DNMTs), using S-adenosyl-
methionine (SAM) as a methyl group (CH3) donor and consists in adding the methyl group 
to the 5’carbon of cytosine, originating 5-methylcytosine (5mC) (Figure 4)  [87, 103]. DNMTs 
family includes 5 members: DNMT1, DNMT2 and DNMT3 (DNMT3A, DNMT3B and 
DNMT3L), wherein only DNMT1, DNMT3A and DNMT3B possess methyltransferase 
activity. DNMT2 is involved in methylation of RNA  [104, 105]. DNMT1 is a maintenance 
methyltransferase responsible for propagation of original methylation patterns during 
somatic cell divisions, initially established by de novo methyltransferases. DNMT1 
preferentially acts on hemi-methylated DNA during replication. DNMT3A and DNMT3B are 
de novo methyltransferases responsible for establishment of DNA methylation patterns 
during embryogenesis, that act independently of replication on unmethylated and hemi-
methylated DNA [85, 86, 106]. Unlike DNMT3A and DNMT3B, DNMT3L is catalytically 
inactive since it lacks the catalytic domain that binds to SAM, but acts as a regulator factor 
that interact with catalytic domains of DNMT3A and DNMT3B stimulating their function as 
de novo DNMTs [107].  
 
 
 
 
 
 
 
Figure 4. DNA methylation reaction: conversion of a cytosine to 5-methylcytosine catalyzed by DNA 
methyltransferases (DNMTs). These enzymes promote the addition of a methyl group (CH3) from S-adenosyl-
methionine (SAM) to 5’carbon of cytosine. SAH: S-adenosyl-homocysteine.   
In human genome about 75% of all CpG dinucleotides are methylated [104]. CpG sites 
are not randomly distributed in genome, since these are especially clustered in short CpG-
dense stretches named CpG islands and in regions of large non-coding repetitive 
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sequences such as centromeres and retrotransposons [86]. CpG island is defined as a 
region with more than 200 base pairs, G+C content of at least 50% and observed-to-
expected CpG frequencies ratio of, at least, 0.6 [105]. CpG islands are preferentially located 
in transcriptional start sites of human genes, occupying about 50-60% of human genes 
promoters, which show the important role of these regions in transcriptional regulation [106, 
108].  
In normal mammalian cells, the CpG dinucleotides within CpG islands are usually 
unmethylated, maintaining an open state of chromatin, allowing gene transcription (Figure 
5). Nevertheless, some of these regions become methylated in a tissue-specific manner 
during development, leading to gene silencing such as the epigenetic silencing of 
chromosome X and in imprinted genes [86, 104, 108]. Furthermore, DNA methylation may 
also occur in CpG islands shores closely located to CpG islands, which are also 
unmethylated in normal human cells [105]. In contrast, the CpG dinucleotides found in non-
coding repetitive elements and gene bodies are often heavily methylated preventing 
chromosomal instability (through silencing non-coding DNA and transposable DNA 
elements) and avoiding transcription initiation in incorrect sites, respectively (Figure 5) 
[105].  
DNA methylation is involved in several cellular processes and its dysregulation has been 
associated with the development of cancer, being involved in initiation, progression, 
invasion and metastases formation. There are two main altered methylation patterns in 
malignancies, namely global DNA hypomethylation and local hypermethylation of specific 
CpG islands, mainly in TSG promoters (Figure 5) [87, 105]. Indeed, 20-60% of tumor cells 
are characterized by global loss of methylation when compared to normal cells [105]. DNA 
hypomethylation was one of the first epigenetic alterations associated with cancer and 
occurs particularly in repetitive sequences, retrotransposons, coding regions and introns 
that are usually methylated [102]. The consequences associated with loss of methylation 
include chromosomal instability, reactivation of genes implicated in cancer, oncogenes 
activation and loss of imprinting [86, 102]. TSG are involved in various biological functions 
including cell cycle, DNA repair, cellular interactions, apoptosis and angiogenesis. Promoter 
hypermethylation in these genes result in their inadequate inactivation and constitutes the 
major event of cancer’s initiation and progression [102].   
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Figure 5. DNA methylation in normal and cancer cells. In normal cells, CpG islands localized in the genes’ 
promoter are unmethylated (cytosine, open lollipops), maintaining an open conformation of chromatin 
(euchromatin state) and, consequently, allowing gene transcription (large gray arrow). In contrast, the CpG 
dinucleotides localized outside the promoter are heavily methylated (cytosine, black lollipops), characterized by 
a closed conformation of chromatin (heterochromatin) and therefore, transcription inactivation. In cancer cells 
the reverse pattern of normal cells is observed: CpG islands of genes’ promoter become abnormally methylated 
(cytosine, black lollipops), leading to transcriptional silencing (large gray arrow with red X), while the regions 
outside of promoter become unmethylated (cytosine, open lollipops), allowing gene transcription. Blue box 
represent exons.  
DNA methylation is associated with a repressive state of chromatin, resulting in 
transcription inhibition and, consequently, gene expression repression. Gene silencing can 
occur either by directly blocking the binding of transcription factors to their specific DNA 
target sites and/or indirectly through recruitment of methyl-CpG-binding (MBD) proteins 
(MBD1, MBD2, MBD3, MBD4, methylcytosine-binding protein 2 (MeCP2) and kaiso), which 
recognize and bind to methylated CpG sites [105, 108]. These proteins may recruit 
chromatin remodeling co-repressor complexes such as histone deacetylases and histone 
methyltransferases which, in turn, may induce chromatin remodeling, important in gene 
silencing [109].  
 
2.2. Epigenetic Alterations in Testicular Germ Cell Tumors 
The foremost epigenetic alterations described for TGCT have already been compiled in 
a review of the literature, published in Epigenomics 2017 [Costa AL et al. “The Epigenetics 
of Testicular Germ Cell Tumors: Looking for Novel Disease Biomarkers” (Annex I)]  [110]. 
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Particularly, in this study we focus in DNA methylation dysregulation, specifically in 
CRIPTO, HOXA9, MGMT, RASSF1A and SCGB3A1 genes. Five genes localization in 
genome and biological function were stated in Table 6. 
 
 Table 6. Five genes localization in genome and biological function. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Locus  Function Reference 
CRIPTO 3p21.31 
Essential during embryogenesis; involved in 
stem cell self-renewal and pluripotency in 
human embryonic stem cells 
[111] 
HOXA9 7p15.2 
Homeobox family genes are involved in 
regulation of morphogenesis, cell differentiation 
and determination of cell identity 
[112] 
MGMT 10q26.3 
Involved in DNA repair, whose protein protects 
cells from promutagenic O6-methylguanine 
alkylation by removing of DNA adducts formed 
by alkylating agents 
[113] 
RASSF1A 3p21.31 
TSG involved in multiple biological pathways  
such as apoptosis, cell motility and invasion 
and cell cycle regulation  
[114] 
SCGB3A1 5q35.3 TSG involved in apoptosis, cell cycle control 
and suppression of cell migration and invasion [115] 
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II. AIMS OF STUDY 
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TGCT are a heterogeneous group of tumors, although most of them share the same 
cytogenetic and genetic background, as stated above. Furthermore, the classical serum 
tumor markers have low sensitivity and specificity for TGCT detection, with only 60% of 
TGCT patients exhibiting elevated levels of these markers at diagnosis. Nonetheless, 
epigenetic alterations that underlie the diversity of TGCT phenotypes and behavior, might 
constitute potential biomarkers for TGCT and provide additional information to standard 
diagnosis tools (clinical, serological, imagiological and pathological parameters). 
Importantly, CRIPTO, HOXA9, MGMT, RASSF1A and SCGB3A1 promoter methylation has 
been reported for these tumors, as described in the literature review included in Annex I. 
Therefore, the main goal of this master dissertation is to evaluate the methylation pattern 
of five genes promoters among TGCT subtypes and assess their potential as methylation-
based biomarkers for subtype discrimination, as well as identify biological differences 
among TGCT subtypes, thus explaining its heterogeneity.  
 
Specifically, the major aims are:  
 Validate a five-genes (CRIPTO, HOXA9, MGMT, RASSF1A and SCGB3A1) 
promoter methylation panel in a retrospective cohort of TGCT and normal 
tissues to assess its value as biomarker of neoplasia;  
 Assess whether specific genes methylation profiles are associated with different 
histological TGCT subtypes and how they do correlate with standard 
clinicopathological parameters; 
 Evaluate the prognostic value of the promoter methylation levels of the five 
genes in TGCT. 
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III. MATERIALS AND METHODS 
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1. PATIENTS AND TISSUE SAMPLE COLLECTION  
Formalin-fixed paraffin-embedded (FFPE) tissue samples from 161 cases of primary 
TGCT [146 related to GCNIS - 76 pure SE and 70 NST (10 pure EmbrCa, 4 pure 
postpubertal-type TE, and 56 mixed germ cell tumors) – and 15 unrelated to GCNIS - 4 
prepubertal-type YST and 11 prepubertal-type TE], diagnosed between 2005 and 2016 and 
archived at the Department of Pathology at Portuguese Oncology Institute of Porto, Portugal 
were selected for this study. All the components of mixed germ cell tumors were identified 
in representative histological slides (see below), selectively collected and individually 
considered for the purposes of comparisons among TGCT subtypes. Thus, malignant 
TGCT tissue samples included 238 samples of TGCT related to GCNIS – 76 pure SE and 
162 NST (10 pure EmbrCa and 4 pure postpubertal-type TE, as well as 19 SE, 42 EmbrCa, 
36 postpubertal-type YST, 14 CH and 37 postpubertal-type TE as components of mixed 
germ cell tumors). 
All tumor samples were collected from orchiectomy specimens of TGCT patients, prior 
to any systemic treatment, and were routinely fixed and paraffin-embedded for routine 
histopathologic diagnosis and staging. Representative blocks were selected by a 
pathologist in slides previously stained with hematoxylin and eosin (H&E), and relevant 
areas were identified for subsequent DNA extraction. Additionally, 16 non-malignant 
testicular FFPE tissue samples were collected from patients submitted to orchiectomy due 
to testicular inflammatory disease or benign pathology and were used as controls. Relevant 
clinicopathological data of TGCT patients and controls were collected from clinical charts. 
This study was approved by institutional ethics review board (Comissão de Ética para a 
Saúde – CES-IPO-12-017) of Portuguese Oncology Institute of Porto, Portugal. 
 
2. DNA EXTRACTION FROM FORMALIN-FIXED PARAFFIN-
EMBEDDED TISSUES (FFPE) 
DNA was extracted from FFPE tissue samples using FFPE RNA/DNA Purification Plus 
Kit (Norgen, Canada, USA), according to manufacturers’ recommendations with some 
adjustments (detailed protocol in Annex II). Briefly, sections of 10 µm were cut from FFPE 
tissue block, previously selected by a pathologist as mentioned before, using a microtome. 
Tumor areas of interest were macrodissected from these 10 µm sections using a disposable 
sterile scalpel blade and transferred to 1.5 mL safe-lock tubes. The first step consisted on 
deparaffinization of FFPE samples through a series of xylene (VWR Chemicals, France) 
and absolute ethanol (Merck, Germany) washes. Next, the FFPE samples were digested 
by a specific time of incubation with Proteinase K (20 mg/mL) (Nzytech, Portugal) and 
Digestion Buffer A. Then, the lysate containing RNA was collected for RNA purification 
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following a specific protocol, while the pellet containing DNA was further digested for DNA 
extraction. 
Focusing on DNA extraction, Buffer RL and absolute ethanol (Merck, Germany) were 
added to DNA-containing lysate and the solution was loaded onto a DNA Purification Micro 
Column. The last step consists in a series of washes with the provided Wash Solution A. 
Lastly, the purified DNA was eluted in 20 µL Elution Buffer F provided. 
After elution, for each sample, the DNA concentration and respective purification ratios 
were assessed by NanoDrop Lite Spectrophotometer (NanoDrop Technologies, USA) and 
stored at -20°C.  
 
3. SODIUM BISULFITE TREATMENT OF DNA 
Extracted DNA was treated with sodium bisulfite, which consists in a chemical reaction 
where the unmethylated cytosines are converted to uracils, while methylated cytosines 
remains cytosines (Figure 6). Thus, sodium bisulfite treatment of DNA allows discrimination 
between methylated and unmethylated DNA sequences, which can be further analyzed by 
polymerase chain reaction (PCR)-based methods.  
 
 
 
Figure 6. Sodium bisulfite treatment of genomic DNA. In this reaction, the unmethylated cytosines are converted 
to uracils, while methylated cytosines remain unchanged.  
 
Sodium bisulfite treatment of extracted DNA was performed using EZ DNA Methylation-
GoldTM Kit (Zymo Research, CA, USA), according to manufacturers’ recommendations 
(detailed protocol in Annex III). The quantity of DNA used was variable according to DNA 
concentration obtained from each sample. Thus, the quantity of bisulfite-modified genomic 
DNA varied between 250-1200 nanograms and consequently, it was eluted in 12.5-60 µL 
of sterile bidistilled water (B.Braun, Melsungen, Germany) and stored at -80°C. 
CpGenomeTM Universal Methylated DNA (Merck Millipore, Germany) was also modified 
using the same process for further use in quantitative methylation-specific PCR (qMSP) as 
positive control. In the last step, it was eluted in a total volume of 20 µL of sterile bidistilled 
water (B.Braun, Melsungen, Germany).  
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4. QUANTITATIVE METHYLATION-SPECIFIC POLYMERASE 
CHAIN REACTION (QMSP) 
To evaluate the degree of each gene methylation, qMSP method was performed. This 
method allows a specific, sensitive, cost-effective and high-throughput analysis [116]. 
In qMSP, specific primers were used to amplify methylated dinucleotides CpG. For ȕ-
Actin, MGMT and SCGB3A1 genes, primers were selected from the literature [117-119] 
(Table 7). On the other hand, for CRIPTO, HOXA9 and RASSF1A genes, sequence-specific 
primers were designed using in silico PCR tools and synthesized by Sigma Aldrich. The dye 
used to detect DNA amplification was SyBr Green, which emits a fluorescent signal that is 
proportional to the quantity of amplified PCR product. Although, this dye is non-specific 
because it binds to double strand DNA (dsDNA), thus, a melting curve was generated in 
order to assess the presence of non-specific PCR products and primer-dimer [120].   
Bisulfite-modified genomic DNA was used as template to evaluate the methylation 
status of CRIPTO, HOXA9, MGMT, RASSF1A and SCGB3A1 genes and reactions were 
carried out in 384-well plates using LightCycler 480 (Roche, Germany). In brief, 1 µL of 
modified DNA, 5 µL of NZYSpeedy qPCR Green Master Mix (2x), ROX (Nzytech, Portugal), 
a variable volume of primers depending of gene analyzed (Table 7) and sterile bidistilled 
water (B.Braun, Melsungen, Germany), were added in a total volume of 10 µL in each well. 
The thermocycler conditions consisted in an initial step of polymerase activation at 95°C for 
2 minutes followed by 40 cycles at 95°C for 5 seconds and 20 seconds at a variable 
temperature, according to the different primers used (Table 7), for denaturation and 
annealing/extension, respectively. Each sample was carried out in triplicate and, in each 
plate two negative controls and five serial dilutions (in duplicate) of a previously modified 
CpGenomeTM Universal Methylated DNA (Merck Millipore, Germany) were also included. 
Based on these dilutions, a standard curve was generated allowing relative quantification 
and ascertain the PCR efficiency.  
In addition, ȕ-Actin gene was used as internal reference gene for the normalization of 
the assay. The relative methylation level was determined by comparison the mean 
concentration of each target gene for each sample and the mean concentration of ȕ-Actin 
gene for each sample according to the next formula:  𝐌𝐞𝐭ܐ𝐲𝐥𝐚𝐭ܑܗܖ 𝐥𝐞𝐯𝐞𝐥 = 𝐓𝐚𝐫܏𝐞𝐭 ܏𝐞ܖ𝐞 𝜷 − 𝑨𝒄𝒕𝒊𝒏 × ૚૙૙૙ 
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Table 7. Primers sequences and qMSP conditions for each of the analyzed genes.  
Gene Primer sequence 5’-3’ 
Amplicon 
(bp) 
Annealing 
Temperature 
(°C) 
Concentration 
per reaction 
(F+R) 
Reference 
β-Actin 
F:TGGTGATGGAGGA
GGTTTAGTAAGT 
133 60 400 nM [117] 
R:AACCAATAAAACCT
ACTCCTCCCTTAA 
CRIPTO 
F:GAGGCGATTTCGG
TTTATAGAC 
134 60 200 nM n.a 
R:CTAACCCCACGAC
ACCGA  
HOXA9 
F:TATTTAGTCGGTAT
TCGC  
150 60 300 nM n.a 
R:ACCTCGAACGCTT
CCAT 
MGMT 
F:TTTCGACGTTCGTA
GGTTTTCGC 
81 62 400 nM [118] 
R:GCACTCTTCCGAA
AACGAAACG 
RASSF1A 
F:AGCGAAGTACGGG
TTTAATC 
111 60 300 nM n.a 
R:ACACGCTCCAACC
GAATA  
SCGB3A1 
F:GGTACGGGTTTTTT
ACGGTTCGTC 
135 64 400 nM [119] 
R:AACTTCTTATACCC
GATCCTCG 
n.a: Not applicable. 
 
5. STATISTICAL ANALYSIS 
Differences in the five genes promoter methylation levels for all combinations of TGCT 
subtypes and comparisons with controls were assessed by non-parametric Kruskal-Wallis 
test for multiple comparisons. Pairwise comparisons were carried out using non-parametric 
Mann-Whitney U test with Bonferroni’s correction (i.e., dividing the standard p-value by the 
number of the groups included in the multiple comparison analysis). Non-parametric Mann-
Whitney U Test was also used for seeking associations between promoter methylation 
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levels and clinicopathological parameters. In patients diagnosed with mixed TGCT, the 
highest methylation value of mixed components was considered for comparing genes 
promoter methylation levels and clinicopathological features. 
The biomarker performance of each gene and of the different combinations of genes 
was assessed through receiver operating characteristics (ROC) curve construction. For 
each gene, a ROC curve was constructed plotting sensitivity (true positive) against 1-
specificity (false positive) whereas for genes-panel, a logistic regression model was used. 
For each gene, a cut-off was established by ROC curve [sensitivity + (1-specificity)], to 
maximize the sensitivity and specificity. In addition, area under the curve (AUC), sensitivity, 
specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy 
were ascertained for each gene individually and for the different genes-panels (Table 8). 
For this analysis, a given genes-panel methylation test was considered positive when at 
least one of the genes tested was positive individually. Moreover, methylation frequencies 
were determined for each TGCT subtype using the highest (for hypermethylation) and 
lowest (for hypomethylation) values of controls as methylation cut-offs for each gene. 
Five genes methylation levels were correlated with patients’ age using a Spearman non-
parametric correlation test.  
Globally, results were considered statistically significant when p-value<0.05. Statistical 
analysis was performed using SPSS Statistics, version 24 (IBM-SPSS, IL, USA) and 
GraphPad Prism 6 (GraphPad Software, CA, USA).  
 
Table 8. Biomarkers performance calculation for each gene. 
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IV. RESULTS 
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1. CLINICAL AND PATHOLOGICAL DATA 
All clinical samples from orchiectomy specimens included in this study were treatment 
naive. The median age of patients included was 30 years (range 13 to 52) for GCNIS-related 
TGCT and 16 years (range 1 to 35) for GCNIS-unrelated TGCT. The majority of GCNIS-
related cases (52.1%) presented SE (76/146), whereas 47.9% presented NST (70/146), 
being 14.3% of EmbrCa (10/70), 5.7% of postpubertal-type TE (4/70) and 80.0% of mixed 
tumors (56/70). Concerning GCNIS-unrelated TGCT, 73.3% of cases presented 
prepubertal-type TE (11/15) followed by prepubertal-type YST (4/15). Most of patients 
(63.7%) with GCNIS-related TGCT presented clinical stage I (93/146), whereas only 11.0% 
(16/146) were stage III. According to the International Germ Cell Cancer Collaborative 
Group (IGCCCG) [78], 26.8% (37/138) of the cases were classified at good prognosis, 2.2% 
(3/138) at intermediate prognosis and 3.6% (5/138) at poor prognosis.  
Before surgery, increased levels of AFP, ȕ-hCG and LDH were observed in 35.0% 
(49/140), 51.8% (72/139) and 42.9% (48/112) of GCNIS-related cases, respectively 
(Supplementary Table – Annex IV).  
The most relevant clinical and pathological characteristics of our cohort are described 
in Table 9.  
Table 9. Clinical and pathological characteristics of TGCT patients and controls included in this study. 
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2. ASSESSMENT OF THE DIAGNOSTIC PERFORMANCE OF GENE 
PROMOTER METHYLATION  
CRIPTO, HOXA9, MGMT and SCGB3A1 methylation levels were significantly higher in 
GCNIS-related TGCT compared to controls (p=0.0058, p=0.0092, p=0.0268 and p=0.0156, 
respectively) (Figure 7). However, the diagnostic performance of these markers was 
modest, with AUC values of 0.7033 for CRIPTO, 0.6922 for HOXA9, 0.6282 for MGMT and 
0.6685 for SCGB3A1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Distribution and ROC curve analyses of four genes promoter methylation levels in controls and TGCT 
related to GCNIS. Left panel: Boxplots of (A) CRIPTO, (C) HOXA9, (E) MGMT and (G) SCGB3A1 promoter 
methylation levels in controls and TGCT related to GCNIS. (Mann-Whitney U Test, *p<0.05, **p<0.01). Right 
panel: ROC curve for (B) CRIPTO, (D) HOXA9, (F) MGMT and (H) SCGB3A1 across controls and TGCT related 
to GCNIS. (Dark line: ROC curve for CRIPTO, HOXA9, MGMT and SCGB3A1 genes; light gray dashed line: 
reference line). 
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Conversely, no significant differences between controls and GCNIS-related TGCT were 
found for RASSF1A methylation levels. 
 
Notably, comparisons between pure SE samples vs. controls and between NST 
samples vs. controls, disclosed that CRIPTO, HOXA9, MGMT and SCGB3A1 methylation 
levels were significantly higher in NST (p=0.0002, p<0.0001, p=0.0044 and p<0.0001, 
respectively), whereas RASSF1A promoter methylation levels were significantly higher in 
controls compared with pure SE tissues (p<0.0001) (Table 10 and Figure 8). 
 
Table 10. CRIPTO, HOXA9, MGMT, RASSF1A and SCGB3A1 promoter methylation levels in controls and 
GCNIS-related TGCT. 
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Figure 8. Distribution and ROC curve analyses of five genes promoter methylation levels in controls and pure 
SE or NST samples. Left panel: Boxplots of (A) CRIPTO, (C) HOXA9, (E) MGMT, (G) RASSF1A and (I) 
SCGB3A1 promoter methylation levels in controls, pure SE and NST samples. (Mann-Whitney U Test, **p<0.01, 
***p<0.001, ****p<0.0001). Right panel: ROC curve for (B) CRIPTO, (D) HOXA9, (F) MGMT and (J) SCGB3A1 
across controls and NST samples; ROC curve for (H) RASSF1A across controls and pure SE samples. (Dark 
line: ROC curve for five genes; light gray dashed line: reference line). 
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CRIPTO, HOXA9 and SCGB3A1 promoter methylation levels displayed AUC values 
above 0.75 for discriminating NST from controls (Table 11). Remarkably, HOXA9 showed 
the highest values for all standard validity estimates, except for NPV (28%) (Table 11).  
Moreover, the combination of CRIPTO/HOXA9/SCGB3A1 panel improved the 
diagnostic coverage of NST, with high sensitivity (97.5%), PPV (96.9%) and accuracy 
(94.9%), despite modest specificity (69%) (Table 12 and Figure 9).  
 
Table 11. Performance of gene promoter methylation for NST identification.  
 
 
Table 12. Performance of genes-panel methylation for NST identification.  
 
 
 
 
 
 
 
 
Figure 9. ROC curve for CRIPTO/HOXA9/SCGB3A1 panel across controls and NST samples. (Dark line: ROC 
curve for CRIPTO/HOXA9/SCGB3A1 genes-panel; light gray dashed line: reference line). 
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Concerning discrimination from pure SE, RASSF1A displayed AUC value of 0.8832 
(Figure 8H), corresponding to 87.5% sensitivity, 93.4% specificity, 97.3% NPV and 92.4% 
accuracy, although PPV was only 74%. 
 
3. PROMOTER METHYLATION PROFILE IN TGCT SUBTYPES 
3.1.  Pure Seminomas versus Nonseminomatous Tumors  
Regarding the two major subtypes of GCNIS-related TGCT, CRIPTO, HOXA9, MGMT, 
RASSF1A and SCGB3A1 promoter methylation levels were significantly higher in NST 
compared to pure SE (p<0.0001 for all genes, Table 13 and Figure 10).  
 
Table 13. CRIPTO, HOXA9, MGMT, RASSF1A and SCGB3A1 promoter methylation levels in GCNIS-related 
TGCT.  
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Figure 10. Distribution and ROC curve analyses of five genes promoter methylation levels in pure SE and NST 
samples. Left panel: Boxplots of (A) CRIPTO, (C) HOXA9, (E) MGMT, (G) RASSF1A and (I) SCGB3A1 promoter 
methylation levels in pure SE and NST samples. (Mann-Whitney U Test, ****p<0.0001). Right panel: ROC curve 
for (B) CRIPTO, (D) HOXA9, (F) MGMT, (H) RASSF1A and (J) SCGB3A1 across pure SE and NST samples. 
(Dark line: ROC curve for five genes; light gray dashed line: reference line). 
37 
 
Importantly, for discriminating pure SE from NST, RASSF1A displayed the highest AUC 
(0.8631), sensitivity, specificity, and accuracy (Table 14). Since CRIPTO and MGMT 
promoter methylation displayed AUC values inferior to 0.75, validity estimates were not 
determined.  
 
Table 14. Discriminatory performance of genes promoter methylation between pure SE and NST samples.   
 
 
Several combinations of these three-genes were tested to assess the best performance 
for distinguishing pure SE from NST. Although all combinations displayed an AUC value 
higher than 0.85 (Table 15), the best overall performance was achieved by 
HOXA9/RASSF1A panel with 90.1% sensitivity, 81.6% specificity, 91.3% PPV, 79.5% NPV 
and 87.4% accuracy (Table 15 and Figure 11).  
 
Table 15. Discriminatory performance of genes-panel methylation between pure SE and NST samples. 
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Figure 11. ROC curve for HOXA9/RASSF1A panel across pure SE and NST samples. (Dark line: ROC curve 
for HOXA9/RASSF1A genes-panel; light gray dashed line: reference line). 
 
Concerning aberrant (hyper- or hypo-) promoter methylation frequencies, CH as 
component of mixed TGCT depicted the highest values for SCGB3A1 (12/14), RASSF1A 
(10/14) and HOXA9 (7/14), followed by postpubertal-type TE as component of mixed TGCT 
with HOXA9 (27/37), SCGB3A1 (22/37) and MGMT (21/37). Importantly, RASSF1A 
hypomethylation was observed in 64 out of 76 pure SE (Figure 12). 
 
Figure 12. Aberrant promoter methylation frequencies amongst TGCT histological subtypes. (Mixed: TGCT 
subtypes as components of mixed germ cell tumors; YST: Postpubertal-type YST; TE: Postpubertal-type TE).  
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3.2.  Pure Tumors versus Matching Mixed Forms 
Interestingly, CRIPTO, HOXA9, MGMT, RASSF1A and SCGB3A1 methylation levels 
were significantly different in pure GCNIS-related TGCT comparing with their matching 
mixed forms. Indeed, components of mixed TGCT displayed the highest levels for all 
studied genes. No patients with pure postpubertal-type YST and CH were available to 
perform the same type of analysis. 
 
3.2.1. Pure Seminoma versus Seminoma in Mixed Germ Cell Tumors 
CRIPTO, MGMT and RASSF1A methylation levels were significantly higher in SE as 
component of mixed TGCT compared with pure SE (p=0.0004, p=0.0061, p=0.0220, 
respectively) (Figure 13).  
Figure 13. Boxplots of (A) CRIPTO, (B) MGMT and (C) RASSF1A promoter methylation levels in pure SE and 
SE as component of mixed TGCT samples. (Mann-Whitney U Test, *p<0.05, **p<0.01 and ***p<0.001).  
 
3.2.2. Pure Embryonal Carcinoma versus Embryonal Carcinoma in 
Mixed Germ Cell Tumors 
EmbrCa as component of mixed TGCT showed significantly higher MGMT methylation 
levels when compared with its pure form (p=0.0321) (Figure 14).  
 
 
 
 
 
 
Figure 14. Boxplot of MGMT promoter methylation levels in pure EmbrCa and EmbrCa as component of mixed 
TGCT samples. (Mann-Whitney U Test, *p<0.05). 
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3.2.3. Pure Postpubertal-Type Teratoma versus Postpubertal-Type 
Teratoma in Mixed Germ Cell Tumors 
HOXA9, RASSF1A and SCGB3A1 methylation levels were significantly higher in 
postpubertal-type TE as component of mixed TGCT compared with pure postpubertal-type 
TE (p=0.0305, p=0.0140 and p=0.0099, respectively) (Figure 15).  
Figure 15. Boxplots of (A) HOXA9, (B) RASSF1A and (C) SCGB3A1 promoter methylation levels in pure 
postpubertal-type TE and postpubertal-type TE as component of mixed TGCT samples. (Mann-Whitney U Test, 
*p<0.05, **p<0.01).  
 
3.3. Comparisons Among Pure TGCT Subtypes 
CRIPTO, HOXA9, RASSF1A and SCGB3A1 methylation levels were significantly 
different among the several pure forms of GCNIS-related TGCT (Figure 16, Table 16). 
 
 
 
 
 
 
 
 
 
 
Figure 16. Boxplots of (A) CRIPTO, (B) HOXA9, (C) RASSF1A and (D) SCGB3A1 promoter methylation levels 
in pure TGCT subtypes related to GCNIS. (TE: Postpubertal-type TE; Mann-Whitney U Test, *p<0.05, 
***p<0.001, ****p<0.0001).  
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Indeed, HOXA9, RASSF1A and SCGB3A1 methylation levels in SE differed significantly 
from EmbrCa, whilst CRIPTO methylation levels differed between SE and TE and between 
the latter and EmbrCa. 
 
Table 16. Kruskal-Wallis and Mann-Whitney tests analysis of CRIPTO, HOXA9, RASSF1A and SCGB3A1 
promoter methylation levels between pure GCNIS-related TGCT samples. 
 
 
3.4. Comparisons Amongst the Components of Mixed Germ Cell Tumors  
HOXA9, MGMT, RASSF1A and SCGB3A1 methylation levels significantly differed 
amongst GCNIS-related TGCT subtypes as components of mixed TGCT (Figure 17, Table 
17).  
Overall, for all the analyzed genes, the lowest methylation levels were observed in 
mixed SE. Concerning MGMT, methylation levels did not differ among the different 
subtypes, except between mixed SE and TE. RASSF1A and SCGB3A1 methylation levels 
followed a similar pattern among the components of mixed germ cell tumors. No significant 
differences in methylation levels were found between mixed YST, CH and TE for any of the 
analyzed genes. 
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Figure 17. Boxplots of (A) HOXA9, (B) MGMT, (C) RASSF1A and (D) SCGB3A1 promoter methylation levels 
in GCNIS-related TGCT subtypes as components of mixed TGCT samples. (YST: Postpubertal-type YST; TE: 
Postpubertal-type TE; Mann-Whitney U Test, **p<0.01;***p<0.001, ****p<0.0001). 
 
Table 17. Kruskal-Wallis and Mann-Whitney tests analysis of HOXA9, MGMT, RASSF1A and SCGB3A1 
promoter methylation levels between GCNIS-related TGCT as components of mixed TGCT. 
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3.5. Prepubertal-Type Subtypes versus Matching Postpubertal-Type 
Tumors 
CRIPTO methylation levels were significantly higher in postpubertal-type YST from 
mixed TGCT compared to prepubertal-type YST (p=0.0086) (Figure 18), whereas the 
opposite was depicted for HOXA9 (p=0.0368) (Figure 19). 
 
 
 
 
 
 
Figure 18.  Boxplot of CRIPTO promoter methylation levels in prepubertal-type YST and postpubertal-type YST 
as component of mixed TGCT samples. (Mann-Whitney U Test, **p<0.01).  
 
 
 
 
 
 
Figure 19. Boxplot of HOXA9 promoter methylation levels in prepubertal-type YST and postpubertal-type YST 
as component of mixed TGCT samples. (Mann-Whitney U Test, *p<0.05). 
 
Concerning TE, HOXA9, MGMT and SCGB3A1 methylation levels were significantly 
higher in postpubertal-type TE as component of mixed TGCT compared to prepubertal-type 
TE (p=0.0091, p=0.0051 and p=0.0054, respectively) (Figure 20).  
Figure 20. Boxplots of (A) HOXA9, (B) MGMT and (C) SCGB3A1 promoter methylation levels in prepubertal-
type TE and postpubertal-type TE as component of mixed TGCT samples. (Mann-Whitney U Test, **p<0.01).  
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4. ASSOCIATION BETWEEN GENE PROMOTER METHYLATION 
LEVELS AND CLINICOPATHOLOGICAL PARAMETERS 
In postpubertal TGCT, a significant inverse correlation was found between methylation 
levels of all genes and patients’ age (CRIPTO, HOXA9, MGMT, RASSF1A and SCGB3A1, 
p=0.027, r=-0.183; p<0.001, r=-0.356; p=0.001, r=-0.281; p<0.001, r=-0.375; p<0.001, r=-
0.388 respectively). However, no correlation with age was found when pure SE and NST 
were considered separately. Contrarily, in prepubertal TGCT, a significant positive 
correlation was found between CRIPTO promoter methylation and patients’ age (p=0.005, 
r=0.679). Moreover, no association was found between methylation levels and age of 
controls. 
Considering the potential of five genes promoter methylation levels as diagnostic 
biomarkers, CRIPTO methylation levels displayed higher sensitivity (65.8%) for GCNIS-
related TGCT detection compared to any of the classical serum tumor markers (AFP: 
35.0%; ȕ-hCG: 51.8% and LDH: 42.9%), assessed prior to orchiectomy (Figure 21).  
 
 
 
 
 
 
 
 
 
Figure 21. Graphic representation of sensitivity of CRIPTO methylation assay and classical serum tumor 
markers in TGCT related to GCNIS detection. 
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HOXA9, RASSF1A and SCGB3A1 methylation levels significantly associated with 
advanced stage (stages II and III). Specifically, stage III patients displayed significantly 
higher methylation levels compared with stage I (HOXA9: p=0.0004, RASSF1A: p=0.0007 
and SCGB3A1: p=0.0002) and stage II patients (HOXA9: p=0.0081, RASSF1A: p=0.0138 
and SCGB3A1: p=0.0081) (Figure 22).  
Figure 22. Boxplots of (A) HOXA9, (B) RASSF1A and (C) SCGB3A1 promoter methylation levels in the different 
stages of the disease. (Mann-Whitney U Test, *p<0.05, **p<0.01; ***p<0.001). 
 
Furthermore, HOXA9, RASSF1A and SCGB3A1 methylation levels also significantly 
associated with prognostic-based staging. Indeed, higher methylation levels were depicted 
by patients classified in intermediate or poor prognosis compared to patients with good 
prognosis [HOXA9: p=0.0031 (good vs. poor), RASSF1A: p=0.0103 (good vs. intermediate) 
and SCGB3A1: p=0.0035 (good vs. poor)] (Figure 23). No significant associations were 
found for the remaining genes both for staging and prognostic-based staging. 
Figure 23. Boxplots of (A) HOXA9, (B) RASSF1A and (C) SCGB3A1 promoter methylation levels in the different 
prognostic-based staging of the disease. (Mann-Whitney U Test, *p<0.05; **p<0.01). 
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V. DISCUSSION 
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Although TGCT account for only 1% of all male cancers worldwide, they are the most 
common cancer diagnosed in young Caucasian men [2] and represent a very 
heterogeneous group of tumors, although cytogenetically similar, suggesting that epigenetic 
alterations may contribute for this heterogeneity [121]. TGCT diagnosis is based on an 
extensive characterization of orchiectomy specimens, at morphological and 
immunohistochemical level, performed by trained pathologists. Correct differential 
diagnosis of TGCT is required for therapy decision and prognostication, which is often 
difficult due to TGCT histopathological variability [122]. Serum tumor markers levels 
measured before and after surgery provide additional information for diagnosis and patient 
monitoring. However, they display relatively low sensitivity and specificity for TGCT 
detection [77]. Thus, the identification and validation of new epigenetic-based biomarkers, 
displaying higher sensitivity and specificity, for screening, diagnosis and disease monitoring 
constitute of the main focus of TGCT research at present [77, 123]. The main goal of this 
study was to evaluate whether specific genes methylation profiles associated with distinct 
TGCT subtypes and may, thus, serve as type-specific biomarkers. Indeed, accurate TGCT 
subtype discrimination is essential, providing additional information to standard clinical, 
serological, imagiological and pathological parameters, impacting on staging and 
subsequent therapeutic decisions.  
Based on assessment of aberrant DNA methylation at promoter regions, we firstly 
evaluated the diagnostic performance of a five genes panel. Considering GCNIS-related 
TGCT, we found that CRIPTO, HOXA9, MGMT and SCGB3A1 methylation levels were 
significantly higher compared to controls. This observation contrasts with that of Brait et al. 
in which no significant differences between TGCT and control tissues were disclosed for 
MGMT methylation levels [124]. It should be emphasized, however, that our series more 
than quadruplicates that of Brait and co-workers (238 vs. 57), that might influence statistical 
analysis. Moreover, our control samples were collected from patients with testicular 
inflammatory disease or benign tumors, whereas those used by Brait et al. were obtained 
from patients submitted to surgical castration due to prostate cancer [124]. Nevertheless, 
despite the significant differences in methylation levels, ROC curve analysis disclosed a 
modest AUC value for each gene (not higher than 0.70), limiting its potential as biomarkers, 
individually. 
Interestingly, although no significant differences in RASSF1A methylation levels were 
found between controls and GCNIS-related TGCT in general, significant RASSF1A 
promoter hypomethylation was observed in pure SE tissues. In this setting, the biomarker 
discriminated pure SE from controls with AUC of 0.8832, 87.5% sensitivity and 93.4% 
specificity. The performance of RASSF1A was, thus, superior to that of a previously 
reported gene panel [124]. On the other hand, CRIPTO, HOXA9, MGMT and SCGB3A1 
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promoter methylation levels were significantly higher in NST compared to controls, and a 
panel comprising CRIPTO/HOXA9/SCGB3A1 achieved better performance than individual 
genes, although with modest specificity and NPV (68.8% and 73.3%, respectively). In the 
previously mentioned report, APC/ER-ȕ/MLH1 panel displayed AUC value of 0.89, with 
85.7% sensitivity and 82.6% specificity for NST detection [124]. Nevertheless, direct 
comparisons with our study cannot be made because the composition of NST in Brait et al. 
series was not disclosed, the sample size is smaller and the same cut-off obtained by ROC 
curve analysis to discriminate between tumor and normal tissues was used for all 
comparisons [124]. Concerning methylation frequencies, the highest values for HOXA9, 
RASSF1A and SCGB3A1 were depicted in CH as component of mixed germ cell tumors 
[7/14 (50%), 10/14 (71.4%) and 12/14 (86%), respectively], whilst the highest HOXA9, 
MGMT and SCGB3A1 methylation frequencies were observed in postpubertal-type TE as 
component of mixed germ cell tumors [27/37 (73%), 21/37 (57%) and 22/37 (59.5%), 
respectively]. Lind et al. found that CH subtype displayed the highest HOXA9, RASSF1A 
and SCGB3A1 methylation frequencies [119]. However, only one sample of pure CH was 
included in their study, while in our study all the CH samples (n=14) belonged to mixed 
TGCT. Furthermore, Koul et al. showed that the highest methylation frequencies of 
RASSF1A and MGMT were found in YST and EmbrCa, respectively [125]. Once more, 
comparisons among these studies should be made with precaution, as it should be recalled 
that in our study each component of mixed TGCT subtypes was analyzed separately, while 
in the aforementioned study, mixed TGCT were considered as a single subtype. 
The main goal of this dissertation was to assess the methylation profile of some cancer-
related genes among different TGCT subtypes. Altogether, GCNIS and SE have been 
characterized by global DNA hypomethylation, whereas NST generally disclose increased 
DNA methylation [37, 126]. Thus, a tumorigenic model suggests that SE arises from GCNIS 
cells that retain the methylation erasure that occurs during normal germ cell development, 
and subsequent de novo methylation is related to development of NST [37, 126]. 
Remarkably, our results are in accordance with this proposal, as CRIPTO, HOXA9, MGMT, 
RASSF1A and SCGB3A1 promoter methylation were significantly more common in NST 
compared to pure SE, paralleling other previous observations, although frequencies vary 
among studies [119, 125-128]. These discrepancies might be due to differences in the 
number of samples analyzed in each study (our series is the largest), as well as of the TGCT 
subtypes, since we segregated pure NST from components of mixed TGCT subtypes. 
Moreover, different methodological approaches were used for methylation analysis, with 
most researchers using conventional qualitative MSP, whereas we used quantitative MSP, 
that displays higher sensitivity and specificity [129-131]. Notwithstanding, all these data 
suggest that a methylation panel could discriminate pure SE from NST. Accordingly, we 
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found that the HOXA9/RASSF1A panel displayed the best performance in this setting, with 
90.1% sensitivity, 81.6% specificity and 87.4% accuracy. This result compares well with 
that of Brait et al., which found that APC/MLH1/ER-ȕ/FKBP4 panel could discriminate pure 
SE from NST with 85.7% sensitivity and 93.0% specificity [124]. 
Contrarily to most previous studies aimed at characterizing altered gene promoter 
methylation patterns in TGCT, we decided to segregate “pure” forms of TGCT from those 
composing mixed TGCT. This enabled us to verify whether in morphologically and 
immunohistochemically overlapping lesions (e.g., pure SE and SE foci in mixed TGCT) 
might exist differences in DNA methylation. Remarkably, we found that CRIPTO, MGMT 
and RASSF1A methylation levels were significantly higher in SE as component of mixed 
TGCT than in pure SE, and the same was found concerning MGMT methylation levels in 
EmbrCa as component of mixed TGCT compared to pure EmbrCa. A possible explanation 
is that in mixed TGCT, SE and EmbrCa cells may have already undergone molecular 
alterations that bring them closer to the other NST components compared to their pure form, 
as NST development may result from EmbrCa cell differentiation, that in turn may derive 
from direct reprogramming of GCNIS or SE cells [5]. Thus, although pure TGCT types and 
those composing mixed TGCT are histopathologically indistinguishable [42], they bear 
some differences in promoter methylation levels which could mark progression in this 
cancer model. Importantly, these findings clearly indicate that separate analyses for pure 
TGCT forms and for those collected from mixed TGCT are required, and that they should 
not be lumped together. 
Variations in CRIPTO promoter methylation levels amongst TGCT subtypes might also 
be explained by the same tumorigenesis model. Indeed, we found that CRIPTO promoter 
methylation levels were significantly higher in pure postpubertal-type TE compared to pure 
SE and pure EmbrCa. These results are in accordance in previous observations by Spiller 
et al., which found higher CRIPTO methylation levels in CH, TE and YST, correlating with 
low CRIPTO expression in CH and TE, and low CRIPTO methylation levels in EmbrCa and 
SE, correlating with high CRIPTO expression in EmbrCa [132]. Thus, CRIPTO expression 
seems to be associated with more undifferentiated TGCT (pure EmbrCa and pure SE), 
whereas CRIPTO promoter methylation characterizes more differentiated TGCT (pure 
postpubertal-type TE) [133]. 
TGCT unrelated to GCNIS - prepubertal-type YST and prepubertal-type TE - are a quite 
distinct group, although bearing similar designation to their postpubertal-type counterparts. 
Indeed, prepubertal-type YST morphologically overlaps postpubertal-type YST but it is less 
clinically aggressive, whereas prepubertal-type TE may resemble its postpubertal 
counterpart but they have quite distinct behavior, with the former behaving as a benign 
tumor and the latter as a malignant one [1]. Remarkably, we showed that, at molecular level, 
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CRIPTO and HOXA9 methylation levels significantly differed between prepubertal-type YST 
and postpubertal-type YST as component of mixed TGCT, while HOXA9, MGMT and 
SCGB3A1 methylation levels were also significantly different between prepubertal-type TE 
and postpubertal-type TE as component of mixed TGCT. Thus, it is tempting to speculate 
whether a different epigenetic landscape might contribute to rather dissimilar clinical 
behavior. 
Another aim of this dissertation was to seek for associations between gene promoter 
methylation and standard clinical and pathological parameters. Interestingly, a significant 
negative correlation was found with patients’ age. This result is probably due to the 
methylation profile found for specific TGCT subtypes and their age distribution. Indeed, our 
cohort included NST (n=70) and SE (n=76) with a median patients’ age of 27 and 35 years, 
respectively, which is in accordance with the “bell-shaped” age distribution (NST: 25 years; 
SE: 35 years) reported for these two major TGCT subtypes [25]. Because SE displayed the 
lower gene promoter methylation levels, and affect older patients, a negative correlation 
between methylation levels and age could be expected. A similar explanation applies for 
the association between CRIPTO promoter methylation levels and age in prepubertal-type 
TGCT. Moreover, HOXA9, RASSF1A and SCGB3A1 promoter methylation was 
significantly associated with advanced group staging and with prognostic-based staging for 
metastatic disease. All these genes displayed significantly higher promoter methylation 
levels in stage III disease. Furthermore, HOXA9 and SCGB3A1 methylation levels were 
significantly associated with poor prognosis groups and RASSF1A with intermediate 
prognosis groups. Interestingly, CRIPTO and MGMT promoter methylation did not 
associate with any clinicopathological parameter, which in accordance with previous 
publications [124, 134]. Altogether, these suggest that DNA methylation-based biomarkers 
might improve current risk stratification nomograms, especially for patients with metastatic 
disease, with a possible impact in therapeutic and monitoring strategy. 
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PERSPECTIVES 
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In this study, we showed the potential of methylation-based biomarkers for TGCT 
detection, particularly NST detection, for which CRIPTO/HOXA9/SCGB3A1 panel 
demonstrated an interesting performance. Moreover, we revealed promising methylation 
markers for detection of GCNIS-related TGCT. We confirmed differences in methylation 
patterns, previously reported for SE vs. NST, and we identified a two-gene 
(HOXA9/RASSF1A) panel that might discriminate between these two major TGCT subtypes 
with high sensitivity, specificity and accuracy. Furthermore, our study disclosed, for the first 
time, differences in specific gene promoter methylation levels between “pure” GCNIS-
related TGCT and matching tumor foci from mixed GCNIS-related TGCT, demonstrating 
that despite morphological similarities, there are some differences at molecular level, which 
might be related with this quite unique model of tumorigenesis. Furthermore, differences in 
promoter methylation between pre- and postpubertal TGCT subtypes were also found. 
Finally, HOXA9, RASSF1A and SCGB3A1 promoter methylation levels might provide useful 
information for risk stratification, improving current staging protocols, and might also have 
prognostic value.  
In the future, we aim to evaluate the corresponding genes’ expression in the same 
cohort to determine whether DNA promoter methylation is the main mechanism associated 
with regulation of gene expression among TGCT subtypes, serving as tool for genomic 
plasticity along tumorigenesis. Furthermore, we also intend to validate the genes-panel in 
liquid biopsies, aiming at providing more sensitive and specific biomarkers for TGCT 
detection and monitoring, eventually discriminating among subtypes, complementing 
standard clinical and pathological parameters. Because assessment of gene methylation 
status in cell-free plasma/serum DNA from patients with TGCT has already been reported 
as potential biomarker for TGCT diagnosis [135, 136], they might advantageously replace 
the classical serological tumor markers in routine clinical practice. 
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Abstract  
Testicular germ cell tumors (TGCT) are a group of heterogeneous, biologically diverse and clinically 
challenging neoplasms. Despite the relatively low incidence and mortality rates, a subgroup of patients with 
disseminated disease will relapse after conventional therapy and have a dismal prognosis. Moreover, TGCT 
afflict mostly young men and have therapeutic peculiarities, with some patients showing resistance to 
cisplatin-based treatments and others being troubled by irreversible side effects, such as infertility. Most 
TGCT share a common tumorigenic pathway and are cytogenetically similar, making room for Epigenetics 
to explain its heterogeneity at pathological and clinical level. In this review, we summarize the foremost 
epigenetic alterations among TGCT focusing on their clinical potential as diagnostic, prognostic and 
predictive biomarkers. 
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Introduction 
Despite their rarity, testicular germ cell tumors (TGCT) are the most common cancers in Caucasian men 
between 15 and 44 years in developed countries, accounting for only 1% of all male cancers worldwide, and 
constitute up to 60% of all malignancies diagnosed in men aged 20 to 40 years [1]. Besides representing 
over 95% of testicular neoplasms, germ cell tumors also comprise a small proportion of ovarian 
malignancies, and may even occur at extragonadal sites, mainly along the anatomical midline of the body, 
a fact related to embryogenesis [2]. The overall incidence (1.5 cases per 100.000) has increased over the 
last decades and 65.827 new cases of testicular cancer are expected worldwide in 2030 (i.e., 10.561 more 
than that in 2012) [1, 3]. According to the most recent data, 1 out of every 250 men living in the United States 
will be diagnosed with testicular cancer during their lifetime and out of the 8.720 new cases estimated for 
2016, 380 will die of disease [4]. Remarkably, incidence rates show striking geographical variation, with 
larger increments observed in men living in developed countries, which is consistent with the suggested 
influence of environmental risk factors typical of Western lifestyle, in addition to the well-known impact of 
genetic susceptibility. Early in utero exposure to industrialized lifestyle factors that cause undervirilization of 
the embryo is also in line with the particular predilection of these tumors for young men [5]. In fact, the age 
distribution is approximately “bell-shaped” (median age of 35 years-old for seminomas (SE), 25 for non-
seminomatous tumors (NST) and 30 for mixed tumors), which is presumably explained by the superior 
aggressiveness of NST that entails earlier clinical manifestation. 
 
Clinical relevance 
Opposed to the crescent incidence, TGCT mortality has been decreasing over the past decades, mostly due 
to effective multimodal treatment. TGCT are among the most curable solid neoplasms, with 5-year survival 
rates over 95%. Even when widely metastasized, survival rates are over 80%, reflecting general sensitivity 
to DNA-damaging agents, particularly for SE [4, 6]. This sharply contrasts with the clinical scenario five 
decades ago, when diagnosis of disseminated TGCT meant death within one year for about 90% of patients 
[7]. Putting together both the paucity and good prognosis of TGCT one might argue whether further research 
efforts in this field are still necessary. Nevertheless, there are many reasons for TGCT to remain on the 
brink: despite outstanding cure rates, about 15-20% of patients with disseminated disease will relapse, and 
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late relapses (>2 years after remission), in particular, display poor prognosis; some tumors are resistant to 
cisplatin and the genetic and epigenetic mechanisms underlying this resistance need further clarification; in 
a cancer with such high cure rates, an attempt to reduce morbidity is mandatory, since chemotherapy and 
radiotherapy entail important side effects in young patients (secondary cancers, cardiovascular disease, etc) 
whose real extent is not yet known and that could shift the optimal management to active surveillance; as 
these tumors affect mostly young men, discussion of reproductive health issues is mandatory, namely sperm 
cryoconservation, testosterone supplementation and contraception during chemotherapy; and apart from 
the pathognomonic gain of chromosome 12p [mainly as isochromosome 12p (i12p)], and despite recent 
efforts to discover other genetic/epigenetic foci of susceptibility, no validated molecular markers exist that 
may be used for screening, diagnostic or prognostic purposes [2, 8-13]. 
 
Pathological characterization of TGCT in brief 
TGCT are very heterogeneous neoplasms, probably owing to their origin from pluripotent neoplastic germ 
cells. Natural consequences of this complexity include the diagnostic challenges and dilemmas imposed to 
Pathologists, justifying the various classification schemes created throughout the years. Correct diagnosis 
and staging of TGCT require extensive and systematic sampling of surgical specimens of orchiectomy, as 
well as detailed morphological and immunohistochemical analysis to identify the presence and amount of 
different components, which has profound implications on staging and subsequent therapeutic strategies. 
Moreover, an extensive search for germ cell neoplasia in situ (GCNIS) in the surrounding testicular 
parenchyma should be sought to allow for correct categorization of TGCT, especially in cases of challenging 
differential diagnosis [14-18]. 
Due to TGCT extreme morphological heterogeneity and existence of many unusual patterns, differential 
diagnosis is challenging (Figure 1). SE is the most common type of TGCT, representing about 50% of cases, 
typically displaying a creamy, bulging cut surface and an arrangement in nests/sheets of cells separated by 
fibrous septa containing prominent lymphovascular infiltrate, in clear contrast with spermatocytic tumor (ST), 
a major differential diagnosis. In difficult cases, ST negativity for classic seminoma immunohistochemical 
markers is decisive. Concerning yolk-sac tumor (YST), few differences exist between prepubertal and 
postpubertal subtypes at the morphological level. YST may be incredibly heterogeneous, a feature that might 
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impair their recognition in mixed tumors. Nevertheless, reticular and microcystic patterns are the most 
frequent, and a myxoid stroma is commonly seen. Postpubertal teratoma (TE) usually has a heterogeneous 
cut surface and is composed of elements derived from ectodermal, mesodermal and/or endodermal 
elements. Immature components are frequently admixed with mature tissue but this finding has no 
prognostic significance, in clear contrast with its ovarian counterpart. Conversely, prepubertal TE includes 
epidermoid and dermoid cysts which bear close resemblance to ovarian mature teratomas. Embryonal 
carcinoma (EmbrCa) usually shows a predominantly solid pattern, with remarkable cytological atypia and 
extensive necrosis, whereas choriocarcinoma (CH) is an aggressive tumor (most patients presenting with 
metastatic disease), associated with extensive areas of hemorrhage and necrosis [14].  
 
Cancer model and recent changes in classification 
TGCT are presently separated into two major categories: those related and those unrelated to GCNIS [19]. 
This classification scheme has been recently adopted in the 4th Edition of the World Health Organization 
Classification of Tumours of the Urinary System and Male Genital Organs (released in 2016), shifting from 
an essentially morphological classification, which grouped very distinct tumors under very similar diagnostic 
categories, to a pathogenesis-based classification [20]. 
GCNIS derives from primordial germ cells/gonocytes that fail to differentiate into prespermatogonia and thus 
share many properties with these cells. GCNIS is found in the vicinity of most TGCT (both SE and NST) and 
virtually always progresses to overt cancer. It is also found in the contralateral testis of men previously 
diagnosed with TGCT in approximately 5% of cases. Polyploidization constitutes the initiation step for 
GCNIS formation, which only gains invasive potential after the hormonal changes that occur at puberty, 
progressing then to the default pathway and originating SE, or regaining pluripotency (a phenomenon known 
as “reprogramming)” and originating EmbrCa cells. These might then differentiate into the typical NST 
subtypes: embryonal differentiation originates EmbrCa; extraembryonal differentiation originates 
postpubertal-type YST and CH; and somatic differentiation originates postpubertal-type TE. This 
differentiation process is associated with POU5F1 (OCT3/4) downregulation, a marker constitutively 
expressed in GCNIS, SE and EmbrCa. Indeed, GCNIS-derived neoplasms share many characteristics that 
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unite them in an individual category: similar epidemiology (postpubertal tumors, the most frequent TGCT, 
etc), association with perturbed testicular development, i12p and malignant behavior [21]. 
GCNIS-unrelated tumors are substantially less frequent and include prepubertal YST, prepubertal TE, and 
ST. The former two derive from a more immature primordial germ cell and occur in young children, while the 
latter originates from more mature spermatogonia/spermatocytes and typically afflicts adults aged more than 
50 years. No i12p amplification is detected in these tumors and they mostly follow a clinically benign behavior 
[2, 20, 22]. 
 
Epigenetic aberrations in TGCT and their potential as diagnostic, prognostic & predictive 
biomarkers 
TGCT represent a unique and complex cancer model and despite considerable progress in patient 
management, a complete understanding of all genetic and epigenetic alterations implicated in their genesis, 
which may help identify patients benefiting from additional therapeutic strategies or those that might avoid 
unnecessary treatment, is still an unmet goal [23]. Despite their heterogeneity, most TGCT share a common 
cytogenetic background and, consequently, epigenetic alterations may help illuminate the causes of 
phenotypic and clinical diversity. These alterations might constitute tumor-specific characteristics that may 
add relevant information to standard clinical, serological, imagiological and pathological parameters, 
constituting a novel type of TGCT biomarkers. Indeed, only 60% of TGCT patients exhibit increased levels 
of classical serum tumor markers human chorionic gonadotropin (HCG), α-fetoprotein (AFP), lactate 
dehydrogenase (LDH) or alkaline phosphatase. Thus, discovery and validation of new biomarkers is 
mandatory [24, 25], which should demonstrate higher sensitivity and specificity for diagnosis and disease 
monitoring than the existing ones [26]. For TGCT, the ideal biomarker should be stable in body fluids, exist 
at significantly higher levels in TGCT patients compared to healthy individuals and be detectable regardless 
of the age of the patient, anatomical site of disease or histological subtype [27, 28].  
This review will focus on the foremost epigenetic alterations specifically involved in genesis and progression 
of TGCT, emphasizing their potential as novel cancer biomarkers to assist in clinical management of TGCT 
patients (Tables 1 & 2). 
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DNA methylation 
Generally, cancer cells are characterized by global hypomethylation and locus-specific hypermethylation 
[29]. Interestingly, development of GCNIS has been associated with the period in which the under-
methylated genome of primordial germ cells becomes heavily methylated [30]. Overall, both SE and GCNIS 
are mostly characterized by global hypomethylation, whereas NST exhibit methylation patterns more similar 
to those observed in other cancers derived from somatic cells [30-32]. Thus, promoter methylation status 
might allow for discrimination of TGCT from somatic cancers, which is extremely valuable for clinical 
management, as the differential diagnosis of testicular masses encompasses other lesions (both metastatic 
and even non-neoplastic, such as cysts and inflammatory lesions) and the testicle is seldom subjected to 
diagnostic biopsies given the risks of the procedure. Importantly, because SE and NST have different 
treatment modalities and prognosis, promoter methylation status may assist in the discrimination between 
these two TGCT subtypes [33].  
The XIST gene represents a good example, as its CpG sites are methylated in male somatic cells whereas 
5’ regions are hypomethylated in TGCTs, regardless of gene expression [34]. Indeed, unmethylated XIST 
sequences were detected in 30/31 tissues (SE and NST) and in 16/25 plasma samples from patients with 
TGCT, contrasting with peripheral blood lymphocytes from healthy males (0/14) or plasma from patients 
with non-germ cells tumors (0/24) [34]. Thus, assessment of XIST unmethylated DNA fragments in plasma 
was suggested as a possible biomarker for detection and monitoring of TGCT patients [34]. However, these 
results need confirmation in larger series and attempts to increase sensitivity (e.g., using techniques such 
as real-time PCR [RT-PCR]) are expected to be looked up in the future.  
Concerning gene-specific promoter hypermethylation, several examples have been reported in TGCT. Koul 
et al. evaluated the methylation status of 21 gene promoters in TGCT tissues and cell lines and most of 
them exhibited hypermethylation, although it was not found in controls (normal tissue samples) [33]. 
Interestingly, prevalence of gene promoter hypermethylation was significantly more pronounced in NST than 
in SE (38/63 NST vs. 5/29 SE), with the highest frequency depicted in YST, which might be of value for 
identification of an YST component among mixed TGCT, that may be overlooked. Promoter 
hypermethylation was associated with transcriptional silencing or downregulation of most genes (in all 
tumors for MGMT and MLH1, in 8/10 cases for RASSF1A and 3/5 cases for RARB), which was restored 
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after treatment with 5-aza-2’ deoxycytidine (5-aza-dC), a widely used demethylating agent [33]. MGMT 
encodes for O6-methylguanine-DNA methyltransferase, that under normal conditions protects cells from the 
promutagenic O6-methyguanine alkylation by removing DNA adducts formed by alkylating agents [35]. 
MGMT promoter methylation was observed in TGCT tissues (32/69, 46.4%), contrasting with normal testis 
samples, and at a significantly higher rate in NST (24/35, 68.6%) compared to SE (8/33, 24.2%). Moreover, 
downregulated MGMT expression in six out of seven methylated TGCTs supports an association between 
altered gene expression and development of NST [36]. These results were recently confirmed in another 
study which disclosed that MGMT and CALCA were frequently methylated in NST (MGMT: 20/22, 90.9%, 
p=0.019; CALCA: 19/21, 90.5%, p=0.026) and associated with poor clinical outcome in TGCT patients 
(MGMT: 5-year event-free survival (EFS) rate of 50.5% for promoter methylation vs. 77.1% for unmethylated 
promoter, p=0.032; CALCA: 5-year EFS rate of 51.3% for promoter methylation vs. 77.0% for unmethylated 
promoter, p=0.029) [37]. CALCA methylation was also found to be significantly more common among 
EmbrCa and YST subtypes (p=0.017). Furthermore, CALCA promoter methylation was also significantly 
associated with disease refractory to therapy (9/19, 47.4%, p=0.005 of patients with methylated promoter 
vs. 6/19, 14.0%, p=0.005 of patients with unmethylated promoter status) [37]. Overall, these results suggest 
that gene-specific methylation status may be clinically relevant for prognostication of TGCT patients. Further 
studies on these markers should also be pursued as new treatment modalities targeting DNA methylation 
may be foreseen for refractory TGCT. Nevertheless, no clinical trials testing DNA methylation inhibitors in 
TGCT have been, thus far, conducted. 
More genes have been shown to harbor promoter hypermethylation in NST, including SCGB3A1 / HIN-1 
(19/35 in NST vs. 0/20 in SE), RASSF1A (10/35 in NST vs. 0/19 in SE) and HOXA9 (9/35 in NST vs. 0/20 
in SE) [38], with the lowest levels found in EmbrCa and the highest in TE. This epigenetic dysregulation may 
thus play an important role in TGCT development [38] and might be related with the extent of cell 
differentiation, with progressive increase of methylation along that process. EmbrCa is the most common 
NST subtype, which may be found pure or admixed with other NST. Global methylation analysis of six 
EmbrCa, compared to noncancerous testicular tissues, showed that most differentially methylated regions 
(DMR) in tumor tissues were methylated [39]. Of the nine genes analyzed in those DMR, eight (AGPAT3, 
MIR1184, SUCLG2, RBMY1, SPANXD, RNF168, USP13 and FAM197Y2P) displayed reduced expression 
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in metastatic and nonmetastatic EmbrCa, suggesting that hypermethylation of those promoters might be 
associated with transcriptional repression [39]. Moreover, owing to its association with neoplastic phenotype, 
promoter hypermethylation of those genes might be useful for accurate identification of EmbrCa [39], 
although validation in a larger dataset is required and should include samples from other TGCT subtypes. 
The Nodal/Cripto signaling pathway was recently shown to be involved in deregulation of germ cell 
homeostasis and, thus, implicated in TGCT development [40, 41]. Nodal, a TGFβ family member, signals 
through binding to Activin receptors in the presence of Cripto receptor [41]. Nodal signaling is transiently 
expressed during development of normal stem cells, playing an important role in embryogenesis for 
maintenance of human embryonic stem cells pluripotency, and it is absent in adult tissues [41, 42]. In TGCT, 
Nodal/Crypto signaling is ectopically expressed in NST, with high levels of CRIPTO expression generally 
found in EmbrCa and YST, correlating with promoter hypomethylation in EmbrCa (20%), while low levels 
are depicted in SE, TE and CH, correlating with promoter hypermethylation in TE and CH (72% and 75%, 
respectively) [40]. Because CRIPTO was detected in serum of TGCT patients it was proposed as a novel 
serological marker for TGCT, especially SE, EmbrCa, YST and GCNIS (sensitivity: 33, 40, 33 and 80%, 
respectively). Moreover, assessment of CRIPTO expression in seminal fluid is under study to enhance 
sensitivity of detection [40]. 
Ellinger et al. demonstrated for the first time that detection of hypermethylated cell-free serum DNA may be 
useful for TGCT diagnosis and prognosis [25]. Gene promoter hypermethylation in cell-free serum DNA was 
more frequently detected in TGCT patients than in healthy men (APC: 57.5 vs. 5.7%; p16: 53.4 vs. 17.1%; 
p14: 53.4 vs. 0%; RASSF1A: 46.6 vs. 0%; PTGS2: 45.2 vs. 0%; and GSTP1: 24.7 vs. 0%) [25]. 
Hypermethylation at any gene promoter enabled a better distinction between TGCT patients and healthy 
men than classical serum tumors markers, especially in patients with negativity for conventional markers 
(hypermethylation of two or more gene sites: 67% sensitivity and 97% specificity vs. combination of all four 
classical markers: 58% sensitivity) [25]. 
Most studies on altered DNA methylation patterns in TGCT have been performed in the class of TGCT 
associated with GCNIS, with only a few studies examining the methylation status in prepubertal tumors [43]. 
The pathogenesis of prepubertal YST differs in many aspects from that of its postpubertal counterparts [44, 
45], emphasizing the need for individual analysis of each subtype. This is typified by RUNX3 and APC, 
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which display promoter hypermethylation in prepubertal testicular YST. RUNX3 is a tumor suppressor 
located at 1p36, which demonstrates frequent promoter hypermethylation (8/10 cases) and loss of 
heterozygosity (LOH) (6/8 cases) in prepubertal YST, but not in postpubertal YST (methylation: 0/12; LOH: 
1/6) or normal young testis tissue samples (methylation: 0/10) [45]. APC is another tumor suppressor, 
mapped at 5p21, that exhibits LOH (3/9 prepubertal YST) and promoter hypermethylation (7/10 prepubertal 
YST vs. 0/14 prepubertal normal testis tissue) associated with loss of gene expression (in all seven 
prepubertal YST with APC promoter hypermethylation) in these rare tumors. These data suggest that both 
RUNX3 and APC epigenetic deregulation are likely involved in prepubertal testicular YST pathogenesis [44]. 
The human genome is composed of less than 5% coding sequences, with repetitive sequences comprising 
more than 50% of the genome [46] and these are frequently hypomethylated in cancer cells [47]. The main 
repetitive DNA elements consist of retroelements interspersed, which correspond to about 42% of the 
human genome [48]. Based on their length and promoter nature, these elements can be divided into two 
main groups: long interspersed nucleotide elements (LINEs, 6kb in length), and small interspersed 
nucleotide elements (SINEs 90-300bp in size) [47]. The former comprises three main families – LINE1, 
LINE2 and LINE3 – of which only LINE1 is active [46]. Among SINES, Alu elements are the most abundant 
in humans [47]. Under normal circumstances, LINE1 and Alu elements are densely methylated in human 
tissues [48]. In TGCT LINE1 sequences are hypomethylated in SE and NST, as well as in EmbrCa-derived 
cell lines, contrarily to normal peripheral blood leukocytes (PBL) and normal testicular tissue [48]. 
Interestingly, Alu repeats located at the 5’ end of CDH1 and XIST are hypomethylated in SE but methylated 
in NST, including EmbrCa cell lines, as well as in normal PBL and normal testicular tissue [48]. Moreover, 
demethylation of LINE1 sequences in SE and NST, and of Alu repeats in SE was significantly more extensive 
than in the somatic cancers analyzed (testicular malignant lymphoma and renal cell carcinoma), supporting 
the existence of distinct regulatory patterns of demethylation of repetitive sequences, which may prove 
useful for diagnostic purposes [48]. The differences found for Alu elements methylation between SE and 
NST may prove clinically useful for discriminative purposes in difficult cases or follow-up of patients with 
mixed tumors, owing to the significant differences in prognosis and therapy regimens. 
The TET proteins family (TET1-3) oxidizes 5-methylcytosine to 5-hydroximethylcytosine (5hmC) [49], which 
seems to be associated with epigenetic plasticity [50]. Overall, in normal hierarchically organized tissues, 
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the stem/progenitor cell compartment demonstrates low 5hmC levels, whereas more differentiated cells 
exhibit higher levels, suggesting a relationship between 5hmC and differentiation status [51]. Conversely, 
solid tumors are generally characterized by 5hmC reduced levels [51, 52]. Interestingly, 5hmC levels vary 
among different TGCT subtypes: 5hmC is absent in GCNIS, low levels are present in SE, high levels 
characterize TE, and intermediate levels are found in YST and EmbrCa, whereas 5hmC is detected only in 
stromal and Sertoli cells in the normal testis [50]. This 5hmC profile fits well with the tumorigenic model 
proposed for TGCT and suggests that 5hmC levels may be useful for detection and discrimination among 
different TGCT subtypes [50].  
The vast majority of TGCT respond well to curative-intent treatment with cisplatin-based chemotherapy [29, 
33], having favorable prognosis [53]. More specifically, SE tend to show excellent response to cisplatin-
based chemotherapy, while NST are more variable, depending on the histological composition [29]. 
Nevertheless, a small proportion of patients with metastatic disease are chemoresistant, entailing disease 
relapse and high mortality [33, 35, 53]. Furthermore, high dose cisplatin-based chemotherapy is associated 
with serious cytotoxicity, including renal failure, pulmonary toxicity, vascular disease and infertility [54]. Thus, 
biomarkers predictive of response to chemotherapy might have important clinical usefulness. The role of 
DNA methylation in cisplatin-resistance (in vitro) has been unveiled using Tcam-2 cell line, representative 
of SE, exposed to 5-azacytidine [29]. Overall, demethylating treatment caused decreased resistance to 
cisplatin, suggesting an association between global methylation status and response to chemotherapy [29]. 
Therefore, therapeutic strategies combining standard chemotherapy and epidrugs may be able to overcome 
chemoresistance in TGCT. Another study reported on new genes capable of discriminating NST resistant 
to treatment with cisplatin from those that are sensitive, as well as on novel prognostic markers and 
therapeutic targets [35]. Interestingly, a high incidence of RASSF1A (52% in resistant vs. 28% in sensitive 
tumors) and HIC1 (47% in resistant vs. 24% in sensitive tumors) promoter hypermethylation was associated 
with resistant tumors, whereas MGMT (31% in sensitive vs. 13% in resistant) and RARB (14% in sensitive 
vs. 0% in resistant) promoter hypermethylation was associated with tumors sensitive to cisplatin-based 
regimens [35]. Thus, both global and gene-specific DNA methylation analyses might constitute predictive 
biomarkers for TGCT. 
xiii 
 
In summary, promoter methylation status might be clinically useful for differential diagnosis of testicular 
masses, namely to distinguish TGCT from somatic cancers and further planning the most appropriate 
treatment for SE and NST. Indeed, MGMT and CALCA hypermethylation seems to correlate with NST 
histology (particularly EmbrCa and YST) and poor prognosis. Moreover, CALCA methylation association 
with refractory disease, unravels an opportunity for alkylating agents like temozolomide and DNA 
methylation inhibitors in the treatment of these tumors. Furthermore, RUNX3 hypermethylation may be of 
clinical value for discriminating prepubertal from postpubertal YST, as histology alone might not distinguish 
those subtypes, which has implications on treatment and prognosis, as prepubertal tumors rarely metastize 
or recur and orchiectomy is sufficient. Finally, 5hmC levels seem to correlate well with the tumorigenic model 
of TGCT and might help differentiate between less (SE) and more (TE) differentiated TGCT subtypes.  
 
Histone modifications and chromatin remodeling  
Alterations in histone modifications and chromatin remodeling in TGCT have seldom been studied. There is 
virtually no evidence of key modifications that might be used as diagnostic or prognostic markers in this 
setting. Acetylation of the histone core is a process involved in DNA transcription regulation [55]. In men, 
this post-translational modification regulates spermatogenesis in normal and pathological testes [56]. 
GCNIS cells are characterized by an “open” chromatin status allowing for swift transcription, but at the 
expense of increased likelihood of chromosomal instability, that might foster progression into invasive TGCT. 
This characteristic of GCNIS is supported by low levels of DNA methylation and of repressive chromatin 
markers (H3K9me2, H3K27me3), as well as high levels of activating chromatin markers (H3K4me1/2/3, 
H3K9ac, H2A.Z), contrarily to Sertoli cells [31]. It is believed that ST originate from spermatogonia, although 
no histone modifications were found to match this origin [57]. Indeed, those tumors do not exhibit a 
preferential pattern of activating or repressive marks, making their identification exquisitely difficult [57]. A 
possible association between altered histone methylation patterns and deregulated expression of two genes 
– proto-oncogene POU5F1 (OCT3/4) and tumor suppressor RASSF1A – has been, nonetheless, reported 
[58]. During normal development, POU5F1 functions as a transcription factor involved in pluripotency 
regulation, being expressed in germ and embryonic stem cells [59]. In adult TGCT, this marker is specifically 
expressed depending on the degree of differentiation of each subtype: it is detectable in GCNIS, SE and 
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EmbrCa (consistent with the undifferentiated status and pluripotency) but it is absent in more differentiated 
tumors (YST, CH and TE) [59, 60]. As previously stated, RASSF1A is often silenced in TGCT due to 
promoter hypermethylation [33, 38] but EmbrCa cell lines NTERA2 and NCCIT exposed to a demethylating 
agent demonstrated only a small effect on reduction of methylation at POU5F1 and RASSF1A gene 
promoters [58]. Nevertheless, RASSF1A expression was restored in association with loss of repressive 
mark H3K9 trimethylation and maintenance of activating mark H3K4 trimethylation in its promoter, whereas 
POU5F1 expression was decreased in association with loss of activating mark H3K4 dimethylation. These 
findings suggest that aberrant histone modifications may be key mechanisms underlying POU5F1 (OCT3/4) 
and RASSF1A deregulation in NST [58], but the clinical significance of these findings is still elusive.  
 
Small non-coding RNAs 
Altered patterns of PIWI-interacting RNAs (piRNAs) and piRNA-like transcripts have been implicated in the 
genesis of several cancer types, including TGCT [61]. The PIWI/piRNA pathway plays an important role in 
the development of male germ cells and also in TGCT tumorigenesis [62], possibly due to impaired ability 
to prevent chromatin instability [63]. Indeed, decreased PIWI proteins expression due to promoter 
hypermethylation of corresponding genes (PIWIL1, PIWIL2, PIWIL4 and TDRD1), as well as of piRNAs, was 
previously reported in TGCT primary tissues and cell lines (SE and NST), compared to normal testis [62]. 
This was associated with LINE1 hypomethylation, in agreement with the fact that LINE1 is a target of 
PIWI/piRNA pathway [62]. Global piRNAs downregulation in TGCT, regardless of histologic subtype, was 
recently confirmed [63], and LINE1 hypomethylation in TGCT has also been previously reported [48]. More 
recently, a study using samples from normal testis, TGCT, and adjacent GCNIS found that PIWI1/2/4 
proteins remained expressed in GCNIS adjacent to NST, but were downregulated in GCNIS adjacent to SE 
[64]. As expected, LINE1 was hypermethylated in GCNIS adjacent to NST but not in GCNIS adjacent to SE, 
in accordance with PIWI expression [64]. Thus, loss of LINE1 silencing seems to be involved in the 
development of SE but not NST, suggesting a role for PIWI expression as diagnostic biomarker to 
discriminate between those tumor types [64]. 
Involvement of microRNAs (miRNAs) in TGCT tumorigenesis, in which they may function as oncogenes or 
tumor suppressors [65-67], has been previously documented, and whereas some might represent promising 
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therapeutic targets, others might be of diagnostic or predictive value [63]. MicroRNA-17-92 cluster has been 
shown to be oncogenic in GCNIS, probably due to suppression of apoptosis through inhibition of E2F1 
mRNA translation, leading to progression of GCNIS to invasive TGCT [68]. Moreover, a genetic screen of 
primary human cells identified miR-372 and miR-373 as potential oncogenes in TGCT as well, inducing 
proliferation and tumorigenesis in human cells through cooperation with RAS and neutralization of p53-
mediated CDK inhibition, due to direct targeting of tumor suppressor LATS2 [69]. Likewise, downregulation 
of tumor suppressor gene PTPN23, due to miR-142-3p overexpression, was observed in EmbrCa-derived 
cell lines and SE tissues, compared to mouse spermatogonia-derived cell lines and normal testis, 
respectively [70]. Furthermore, high-throughput screen of 156 miRNAs in postpubertal TGCT, ST, ovarian 
tumors, EmbrCa-derived cell lines and normal testis identified several miRNAs that might discriminate 
different histological subgroups and several target genes, highlighting the importance of miR-371-373 and 
miR-302a-d clusters [71] and confirming previous observations [69]. Recently, miR-371-373 and miR-302 
clusters overexpression was found in malignant testicular and ovarian germ cell tumors, which is consistent 
with downregulation of mRNAs critically involved in several biologically significant pathways [66, 72]. Those 
two miRNA clusters are also expressed in human testicular samples containing GCNIS and fetal gonads, 
further supporting that GCNIS builds up from development-arrested gonocytes that persist in the adult testis 
[73]. Given its strong association with TGCT, members of the miR-371-373 and miR-302-367 clusters [66, 
72] may constitute good biomarkers for TGCT detection and monitoring [63], as well as possible therapeutic 
targets [66, 72]. Nevertheless, it should be noted that in some reports, pediatric and adult YST have been 
included in the same category [72], although they likely represent quite distinct diseases and this might 
affect the analysis of biomarker performance. 
Some miRNAs deregulated in cancer and abundantly expressed in cancer tissues may be detected in body 
fluids owing to its stability [24], and might be useful as noninvasive serum biomarkers [26]. Pre-operative 
expression of miR-371-373 in serum of patients with clinical stage I TGCT was found to be significantly 
higher than in controls (healthy males), and decreased after orchiectomy, suggesting a role for this miRNA 
as a serum TGCT biomarker [24]. This is in line with the previous observation of high serum levels of 
members of the miR-371-373 and miR-302 clusters in a 4 year-old boy with YST, at diagnosis, and 
subsequent decrease during chemotherapy [74]. Moreover, significantly increased miR-367-3p, miR-371a-
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3p, miR-372-3p, and miR-373-3p expression levels were found in sera from patients with TGCT compared 
to controls (healthy men and men with benign testicular disease) [26, 75]. In particular, serum miR-371a-3p 
was more sensitive (84.7%) and specific (99%) for this distinction [26], allowing for improved TGCT detection 
compared to classical serum markers [26, 75]. In patients with clinical stage IA disease, miR-371a-3p levels 
returned to basal values after orchiectomy, further supporting the tumor specificity of this miRNA [26, 76]. 
These results confirmed observations from other research teams [76] and the biomarker performance of 
serum miR-371a-3p was also emphasized due to the association between serum levels and tumor volume, 
absent expression in nontesticular disease and the high levels detected in testicular vein blood [26, 75-77]. 
Interestingly, miR-367 also appears to be a promising TGCT serum marker [26, 75], and its combination 
with miR-371a-3p may further increase the sensitivity and specificity of the test [77]. Remarkably, serum 
miR-371a-3p expression levels were recently shown to detect TGCT with diagnostic sensitivity superior to 
that of classical biomarkers AFP, HCG and LDH (87.8 vs. 50.4%), and an accuracy comparable to those of 
a panel consisting of miR-371a-3p, miR-372-3p, miR-373-3p, and miR-367-3p [78]. Importantly, this study 
included a large series of patients, encompassing both SE and NST (postpubertal subtypes), and it was 
able to replicate the findings of previous pilot studies [24, 26, 27, 75, 76, 78]. Because miR-373-3p serum 
levels decreased after therapy, and its persistence heralded disease persistence and/or relapse, there is 
great potential for patient monitoring [78]. Nevertheless, a major downside of miR-373-3p lies on its lack of 
expression in postpubertal TE, although the clinical impact of this finding is not clear at this point [78]. 
Nonetheless, since miR-373-3p expression was not tested in tumor tissue of TGCT subtypes, it is not known 
whether its assessment might allow for the identification of a particular TGCT subtype. 
In addition to a promising role as serum biomarkers for diagnosis or monitoring, miRNAs have also been 
associated with TGCT sensitivity to cisplatin-based chemotherapy. Interestingly, miR-302a upregulation in 
cisplatin-treated EmbrCa-derived cell lines improves cisplatin-induced apoptosis through downregulation of 
p21 expression and p53 silencing, and increases the lethal effects of cisplatin through reduction of apoptotic 
threshold [54]. Hence, this synergistic effect may set the basis for a novel therapeutic approach for TGCT 
patients, minimizing the adverse effects of cisplatin [54]. A more comprehensive expression analysis of 
almost all human miRNAs in three cisplatin resistant sublines (derived from cisplatin sensitive TGCT cell 
lines) showed that the miR-371-373 cluster may induce resistance in vitro, possibly by neutralizing p53-
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mediated cell death effects [79]. Many other miRNAs have been shown to be up or downregulated in those 
cisplatin-resistant cell lines [79], emphasizing the complexity underlying deregulated miRNAs expression in 
TGCT. In vivo analysis of these miRNAs in cisplatin-resistant tumor tissues is the next expected step that 
may provide useful knowledge and clinical insight on therapy-resistant TGCT.  
MicroRNAs might also constitute therapeutic targets. MiR-199a displays anti-proliferative and anti-invasive 
effects, acting as tumor suppressor in TGCT [80] and it is downregulated, due to promoter methylation, in 
NT2 cell line (representative of TGCT) compared to HT cells (normal testicular fibroblasts) [81]. Remarkably, 
downregulation of miR-199a-3p (one of the mature forms of miR-199a) is associated with DNMT3A2 
overexpression in tumor tissues (SE and EmbrCa) [82]. The therapeutic use of miR-199a-3p synthetic 
oligonucleotides in TGCT was suggested, because increased expression of this miRNA in NT2 cells restored 
APC and MGMT gene expression through promoter demethylation, possibly due to its effect on DNMT3A2 
[82]. More recently, a miR-199a/miR-214/PSMD10/TP53/DNMT1 self-regulatory network was reported in 
TGCT, substantiating the concomitant downregulation of miR-199a along with miR-214, and TP53 [83]. 
Furthermore, overexpression of DNMT1 and PSMD10 was observed in NT2 cells and EmbrCa tissues, 
compared to HT cells and normal tissues, respectively [83]. Thus, disruption of either pathway involving 
miR-199a may contribute to development of TGCT and may constitute a new therapeutic strategy [81, 83]. 
Other studies, addressing both testicular and ovarian germ cell tumors, have demonstrated abundant LIN28 
expression in malignant TGCT, regardless of patient age, tumor location or histological subtype, resulting in 
downregulation of the tumor suppressors miRNAs let-7 family, which target MYCN [84, 85], uncovering 
another potential therapeutic target. 
In summary, loss of LINE1 silencing might assist clinicians in the important distinction between SE and NST; 
determination of miR-371-373 expression in serum both preoperatively for establishing a baseline value and 
post-surgery may be important for follow-up purposes; miR-371a-3p appears to be one of the most 
promising serological markers for TGCT detection a monitoring after treatment, with sensitivity and 
specificity higher than currently used markers. 
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Conclusion & future perspectives 
Despite recent advances in our knowledge and understanding of TGCT, many questions remain 
unanswered: in such a treatment-responsive disease, what drives some tumors to resist and relapse? Which 
mechanisms underlie different behavior for neoplasms that share similar background? Furthermore, in a 
disease mostly afflicting young men and displaying high cure rates, issues concerning quality of life are to 
become more and more important. TGCT require an improved multidisciplinary and patient-centered 
approach for a better suited management of disease [21, 86]. 
Several critical questions relating to TGCT biological characteristics and clinical behavior await more 
definitive answers and Epigenetics may hold the key to improve current knowledge with impact on patient 
management through the development of novel biomarkers (Figure 2). How can epigenetic-based 
biomarkers improve TGCT patients’ management? Biomarkers for disease detection and patient monitoring 
are those with more promising results thus far. Although serum DNA methylation-based markers, especially 
promoter methylation of APC, p16, p14, RASSF1A, PTGS2 and GSTP1, have outperformed classical TGCT 
serum markers (AFP, HCG, LDH), the most robust candidate is undoubtedly serum miR-373-3p. Indeed, 
this biomarker surfaced from a series of pilot studies that coherently demonstrated its sensitivity and 
specificity as a TGCT biomarker, and these findings were very recently validated in a larger study from a 
single center. Nevertheless, external validation in a larger set of patients is required to fully confirm these 
promising results. As previously stated, TGCT constitute a very heterogeneous and complex group of 
tumors, entailing different therapeutic strategies. In this setting, accurate discrimination among TGCT 
subtypes might be of clinical relevance and promoter methylation of MGMT, HIN1, RASSF1A and HOXA9 
might be a valuable ancillary tool, eventually complemented by expression levels of CRIPTO, PIWI, or 
miR371-373 and miR302-367 clusters. It should be noted, however, that most of these results were not 
validated in independent datasets.  
To the best of our knowledge, no epigenetic-based prognostic biomarker has been suggested for TGCT. 
This might be related to the overwhelmingly favorable prognosis of these neoplasms. Nevertheless, there 
are indeed patient subgroups with poorer prognosis, especially those resistant to cisplatin-based therapy. 
Thus, biomarkers predictive of that condition might be of great clinical value. Although reported findings 
might still be considered preliminary, promoter methylation analysis of RASSF1A, HIC1, RARB and MGMT, 
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as well as quantitative expression of miR-371-373 cluster show promise as predictive biomarkers in this 
setting. Moreover, epidrugs might also prove useful for treatment of cisplatin-resistant TGCT, in particular 
the demethylating agents. Finally, there are opportunities for targeting epigenetic aberrations underlying 
TGCT development and progression, as exemplified by miR-199a-3p synthetic oligonucleotides. It is 
noteworthy that prediction of treatment resistance may allow patients to avoid futile side effects and 
eventually benefit from alternative therapeutic modalities. 
To foster the finding and validation of clinically relevant epigenetic biomarkers in TGCT it is now critical to 
conduct integrated analysis of possibly interconnected processes taking place in TGCT biology, such as 
crosslink analysis of DNA methylation, miRNAs expression, gene expression and genotype data, as recently 
accomplished for germ cell tumors in general [87]. In parallel, it is critical to conduct larger, multicentric, 
studies aimed at the validation of the most promising biomarker candidates, thriving for standardized 
protocols encompassing sample collection, storage and molecular analysis. It is likely that increased 
understanding of TGCT epigenetics will prove useful for patient management, complementing and adding 
information to an accurate clinical, pathological and molecular characterization of this disease [88]. 
miRNAs may also be used for therapeutic purposes, as exemplified by the use of miR-199a-3p synthetic 
oligonucleotides for targeting epigenetic aberrations in TGCT.  
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Executive summary 
Testicular germ cell tumors 
Introduction 
TGCT represent over 95% of testicular neoplasms and despite accounting for only 1% of all male cancers worldwide, they comprise 
the most common malignancies in Caucasian men aged between 15 and 44 years-old in developed countries.  
Clinical relevance 
Incidence is rising, as opposed to the descendant death rates, mainly due to multimodal therapy. However, these tumors still impose 
several problems, namely the poor prognosis of late relapses and the emergence of treatment resistance. In such a curable disease, 
issues concerning quality of life, active surveillance and reproductive health are to become more relevant. 
Pathological characterization of TGCT in brief 
TGCT constitute a very heterogeneous group of tumors. A proper pathological evaluation is mandatory for the correct diagnosis and 
staging of these neoplasms. The existence of many unusual patterns makes differential diagnosis challenging. 
Cancer model and recent changes in classification 
There are two major categories of TGCT: those related and those unrelated to GCNIS. This classification has been recently adopted 
by the WHO and more closely reflects the pathogenesis of these neoplasms. 
Epigenetic aberrations in TGCT and their potential as diagnostic, prognostic and predictive biomarkers 
 
DNA methylation 
 Promoter hypermethylation of APC, p16, p14, RASSF1A, PTGS2 and GSTP1 genes showed more utility for TGCT diagnosis 
and prognosis than classical serum tumors markers; 
 Promoter methylation of CALCA is associated with refractory disease;  
 There are promising results associated with gene-specific methylation, in particular for MGMT, HIN1, RASSF1A and HOXA9, 
which might help discriminate among tumor subtypes;  
 Novel biomarkers are also being uncovered for prepubertal tumors, such as hypermethylation of RUNX3 and APC genes;  
 Promoter methylation status of RASSF1A, HIC1, RARB and MGMT genes suggest them as promising predictive biomarkers 
of TGCT response to cisplatin-based therapy; 
 
Histone modifications and chromatin remodeling 
 There is no evidence of major histone modifications and chromatin remodeling associated with TGCT diagnosis or prognosis. 
However, there is a possible relationship between altered histone methylation patterns and deregulated expression of 
POU5F1 (OCT3/4) and RASSF1A; 
 
Small non-coding RNAs 
 Decreased PIWI expression was suggested as a potential diagnostic biomarker for TGCT; 
 The most promising and robust biomarker for diagnosis and monitoring of TGCT is serum miR-373-3p, given its high 
sensitivity and specificity; 
 Quantitative expression of the miR-371-373 cluster might prove useful as a predictive biomarker in TGCT; 
 miRNAs may also be used for therapeutic purposes, as exemplified by the use of miR-199a-3p synthetic oligonucleotides 
for targeting epigenetic aberrations in TGCT. 
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Figure legends 
 
Figure 1 – Testicular germ cell tumors subtypes. A-C – Tumors unrelated to germ cell neoplasia in situ 
(A – Teratoma, prepubertal-type: epidermoid cyst; B – Yolk-sac tumor, prepubertal-type; C – Spermatocytic 
tumor). D-I – Tumors derived from germ cell neoplasia in situ (D – Teratoma, postpubertal-type; E – Yolk-
sac tumor, postpubertal-type; F – Seminoma; G – Embryonal carcinoma; H – Choriocarcinoma; I – Mixed 
germ cell tumor: Teratoma [75%] and Seminoma [25%]). [Hematoxylin and Eosin (H&E) staining] .J – 
Macroscopical aspect of a Seminoma.  
 
Figure 2 - Potential epigenetic markers for detection of testicular germ cell tumors. (Genehyper, Gene 
promoter hypermethylation; Genehypo, Gene promoter hypomethylation; miR, microRNA). 
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Table 1- Diagnostic information provided by epigenetic-based biomarkers in testicular germ cell tumors. 
Cancer detection 
 Biomarker Epigenetic deregulation Sample-type details 
DNA methylation 
XIST (97% TGCT tissues (SE and 
NST) and 64% plasma samples) 
[34] 
Unmethylated DNA XIST fragments (SE 
and NST) 
Primary TGCT tissue:  n=31 (18 SE and 13 NST); 
Plasma from 31 patients with TGCT:  n=25; 
Controls: Peripheral blood lymphocytes from healthy males and 
females; Plasma from 24 male non-TGCT patients (14 renal cell 
carcinoma and 10 bladder carcinomas) 
 MGMT (20.7% [33] and 46% [36]) 
RARB (7.6%) [33] 
RASSF1A (21.7%) [33] 
MLH1 (4.3%) [33] 
Promoter hypermethylation (SE and NST) 
TGCT tissue: n=92 (29 SE, 44 NST and 19 mixed tumors); 
Controls: DNA and RNA isolated from 4 normal testes [33] 
Blood and primary TGCT: n=70 [33 SE (25 from patients with 
pure SE and 8 from patients with mixed tumors)], 35 NST and 
2 GCNIS [36]  
 
 
 
HOXA9 (25.7% NST vs. 0% SE), 
RASSF1A (28.6% NST vs. 0% 
SE), SCGB3A1/HIN-I (54.3% NST 
vs. 0% SE) [38] 
Promoter hypermethylation (NST) 
 
TGCT tissue: n=61 
- DNA from 55 primary TGCT: 20 SE and 35 NST (16 EmbrCa, 
9 TE, 6 YST, 1 CH, 3 mixed tumors); 
- 7 GCNIS lesions; 
Cell lines: n=3; Controls: normal tissue from 4 testes 
 CRIPTO (75%, 72% and 20% of 
methylation in CH, TE and 
EmbrCa, respectively) [40] 
 
Promoter hypermethylation associated with 
low expression of gene (CH and TE) 
Promoter hypomethylation associated with 
high gene expression (EmbrCa) 
TGCT tissue: n=35 [7 SE and 28 NST (5 CH, 4 TE, 9 EmbrCa, 
10 YST)]; 
Controls: 10 JKT-1 cell line 
 RUNX3 (80%) [44] Promoter hypermethylation (YST in infants) Testicular pure YST tissue: n=10; Controls: 12 NST of adulthood; 10 testes of young individuals 
 
APC (70%) [45] Promoter hypermethylation (YST in infants) Testicular pure YST tissue: n=10; Controls: 16 normal testes (2 fetal testes and 14 infantile testes) 
MicroRNAs 
(miRNAs) miR-371a-3p: a) 84.7% sensitivity and 99% 
specificity [26]   
b) 88.7% sensitivity and 93.4% 
specificity [78] 
Increased in patients with TGCT compared 
to healthy individuals and patients with 
benign testicular disease 
a) Serum of patients with TGCT: n=59 (40 SE and 19 NST); 
and with nonmalignant disease: n=17; Controls: 84 healthy 
male individuals [26] 
b) Serum of patients with TGCT: n=166 (96 SE, 60 NST and 10 
TGCT of patients with relapse); Controls: 106 male individuals 
(12 healthy and 94 with benign testicular diseases) [78] 
CH: Choriocarcinoma; EmbrCa: Embryonal carcinoma; GCNIS: Germ cell neoplasia in situ; NST: Nonseminomatous tumors; SE: Seminomas; TE: Teratoma; TGCT: 
Testicular germ cell tumors; YST: Yolk-sac tumor. 
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Table 2- Prognostic and predictive information provided by epigenetic-based biomarkers in testicular germ cell tumors. 
Prognostic/Predictive 
 Biomarker Epigenetic deregulation Sample-type details 
DNA 
methylation 
RASSF1A (52% in resistant vs. 28% in sensitive) 
[35] 
HIC1 (47% in resistant vs. 24% in sensitive) 
TGCT [35] 
Promoter hypermethylation associated with 
NST resistance to cisplatin-based combination 
chemotherapy 
NST tissue: n=70 from 60 patients (31 
samples of sensitive tumors obtained 
from 29 patients and 39 samples of 
resistant tumors obtained from 31 
patients) 
 
MGMT (31% in sensitive vs. 13% in resistance) 
[35] 
RARB (14% in sensitive vs. 0% in resistance) [35] 
Promoter hypermethylation associated with 
NST sensitivity to cisplatin-based combination 
chemotherapy 
NST tissue: n=70 from 60 patients (31 
samples of sensitive tumors obtained 
from 29 patients and 39 samples of 
resistant tumors obtained from 31 
patients) 
 MGMT (EFS = 50.5% in patients with methylated 
promoter vs. EFS = 77.1% in patients with 
unmethylated promoter) [37] 
CALCA (EFS = 51.3% in patients with methylated 
promoter vs. EFS = 77.0% in patients with 
unmethylated promoter) [37] 
Promoter methylation associated with lower 5-
year EFS 
Primary TGCT tissues: n=72 (20 SE 
and 52 NST) 
NST: Nonseminomatous tumors; TGCT: Testicular germ cell tumors; EFS: Event-free survival. 
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ANNEX II 
 
DNA extraction from formalin-fixed paraffin-embedded tissue 
DNA was extracted from FFPE tissue samples obtained from orchiectomy specimens 
of patients with and without TGCT, using FFPE RNA/DNA Purification Plus Kit (Norgen, 
Canada).  
Representative block of each case was previously selected by a pathologist and tumor 
areas were also delimited by the same in slides stained with H&E. Sections of 10 µm were 
cut from FFPE block using a microtome and the tumor areas of interest were 
macrodissected from these sections using a disposable sterile scalpel blade and transferred 
to 1.5 mL safe-lock tubes. The number of macrodissected slides varied between 6 and 20, 
according to different tumor area corresponding to each case.  
The first step of DNA extraction consists in desparaffinization of the FFPE samples 
through a series of xylene (VWR Chemicals, France) and absolute ethanol (Merck, 
Germany) washes. In this way, 1 mL of xylene (VWR Chemicals, France) was added to the 
sample followed by 10 minutes of incubation at 50°C and centrifugation at 14,000 x g 
(approximately 10,000 rpm) for 2 minutes. After carefully removing of xylene (VWR 
Chemicals, France) without dislodging the pellet, 1 mL of absolute ethanol (Merck, 
Germany) was added to the sample followed by centrifugation at 14,000 x g (approximately 
10,000 rpm) for 2 minutes and its carefully removal. This step was repeated a second time 
and then, the pellet was left to air to dry for variable time (usually between 2 and 3 hours).  
Next, the FFPE samples were digested by incubation at 55°C for 15 minutes with 300 
µL of Digestion Buffer A and 10 µL of Proteinase K (20 mg/mL) (Nzytech, Portugal) followed 
by placing the sample on ice for 3 minutes and centrifugation at 14,000 x g (approximately 
10,000 rpm) for 3 minutes. The lysate containing RNA was then collected for RNA 
purification following a specific protocol (not detailed here), while the pellet containing DNA 
was further digested for DNA by incubation the sample at 55°C overnight with 300 µL of 
Digestion Buffer A and 50 µL of Proteinase K (20 mg/mL) (Nzytech, Portugal), adding more 
Proteinase K, if necessary, until digestion was completed. After, the samples were 
incubated at 90°C for 2 hours followed by 3 minutes of cool down in ice. In order to remove 
any trace of RNA, 4 µL of RNase A (10 mg/mL) (Sigma-Aldrich, Germany) was added to 
the cooled lysate followed by 5 minutes of incubation at room temperature. 300 µL of Buffer 
RL and 250 µL absolute ethanol (Merck, Germany) were added to the lysate and the 
solution was loaded onto a DNA Purification Micro Colum in two steps, where in each one 
of them up to 600 µL of lysate were applied onto the column and centrifuged at 14,000 x g 
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(approximately 10,000 rpm) for 1 minute. Then, 3 washes steps with 600 µL of Wash 
Solution A were performed. In each of these steps, after added the 600 µL of Wash Solution 
A, the column was centrifuged at 14,000 x g (approximately 10,000 rpm) for 1 minute and 
the flowthrough was discarded. Lastly, the purified DNA was eluted in 20 µL of the provided 
Elution Buffer F [divided in two steps of 10 µL of this buffer followed by centrifugation at 
14,000 x g (approximately 10,000 rpm) for 1 minute].  
After elution, for each sample, the DNA concentrations and respective purifications 
ratios were measured by NanoDrop Lite Spectrophotometer (NanoDrop Technologies, 
USA) and stored at -20°C.  
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ANNEX III 
 
Sodium bisulfite treatment of DNA 
Sodium bisulfite treatment of extracted and quantified DNA was performed by EZ DNA 
Methylation-GoldTM Kit (Zymo Research, CA, USA). The DNA volume used in this process 
was initially calculated according to its concentration, wherein the quantity of bisulfite-
modified genomic DNA varied between 250 and 1200 nanograms. According to different 
DNA volume used for each sample, we added sterile bidistilled water (B.Braun, Melsungen, 
Germany) up to a total volume of 20 µL. For each sample, was also added 130 µL of CT 
conversion reagent solution followed by incubation in Veriti® Thermal Cycler (Applied 
Biosystems, CA, USA) for 10 minutes at 98°C and 3 hours at 64°C (3 cycles of 60 minutes 
each), allowing denaturation and sodium bisulfite conversion of DNA.  After incubation, each 
sample was transferred to corresponding Zymo-Spin ICTM column with 600 µL of M-binding 
buffer and incubated at room temperature for 10 minutes, followed by centrifugation at 
10,000 rpm for 30 seconds. After that, one wash step was performed by adding 100 µL of 
M-Wash buffer and centrifuged at 10,000 rpm for 30 seconds. The next step consists in 
desulphonation by incubation with 200 µL M-Desulphonation buffer at room temperature for 
20 minutes, followed by a centrifugation at 10,000 rpm for 30 seconds. Next, two washes 
steps were achieved adding 200 µL of M-Wash buffer followed by centrifugation at 10,000 
rpm for 30 seconds in each of these steps. Lastly, the columns were placed in a 1.5 mL 
safe-lock tube and DNA was eluted by 5 minutes of incubation at room temperature with a 
volume of sterile bidistilled water (B.Braun, Melsungen, Germany) variable between 6.25 
and 30 µL, according to different quantity of intended modified-DNA, followed by a 
centrifugation at 12,000 rpm for 30 seconds. This step was repeated a second time to obtain 
a total volume of bisulfite-modified genomic DNA ranging between 12.5 and 60 µL, which 
was then stored at -80°C.  
CpGenomeTM Universal Methylated DNA (Merck Millipore, Germany) was also modified 
using this process. In the last step, this DNA was eluted in a total volume of 20 µL of sterile 
bidistilled water (B.Braun, Melsungen, Germany).  
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ANNEX IV 
 
Table 18. Serum tumor markers positivity in GCNIS-related TGCT.  
 
 
